J&J Earnings Q3

Traditional Coverage

1. Key Takeaways from JNJ’s Q3 Call: Remicade, Pipeline, Acquisitions

   Oct 19, 2016 | Stock Rants

   Healthcare giant and industry bellwether Johnson & Johnson JNJ reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations (Read more: J&J Outshines in Q3 Earnings on Strong Pharma Sales). However, shares were down 2.6% on concerns regarding future growth prospects of the company’s blockbuster top-selling drug, Remicade.
2. Stocks to Keep Your Eyes on Johnson & Johnson (NYSE:JNJ), STMicroelectronics NV (ADR) (NYSE:STM)

   Oct 19, 2016 | Wall Street 24

   By David Williams
   
   
   On Tuesday, Johnson & Johnson (NYSE:JNJ) stock opened its trade at $117.38 and after floating in a range of $115.16 to $118.48, settled at $115.41. The stock lost -2.60% in total of its share price. The stock’s 52-week range is $94.28 – $126.07.
3. Gavekal Capital Lowers stake in Johnson & Johnson (JNJ)

   Oct 19, 2016 | Founders Daily

   By Jim Swaby
   
   
   Johnson & Johnson (JNJ) : Gavekal Capital reduced its stake in Johnson & Johnson by 35.86% during the most recent quarter end. The investment management company now holds a total of 73,782 shares of Johnson & Johnson which is valued at $8,673,812 after selling 41,259 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.Johnson & Johnson makes up approximately 2.96% of Gavekal Capital’s portfolio.
4. J&J Sees Growth In 2017, Looks For Bolt-On Deals, Launches Texas Startup Accelerator

   Oct 19, 2016 | Med Device Online

   By Jof Enriquezq
   
   
   Johnson & Johnson (J&J) is expecting above-market growth in 2017 for its medical device business, and is looking for bolt-on acquisitions to further solidify its already strong presence in the orthopedics, general surgery, and cardiovascular product segments.
5. J&J shares lose ground on fears of Pfizer's answer to Remicade

   Oct 19, 2016 | The Village Suntimes

   By Jay Jacobs
   
   
   In Europe - where Remicade is marketed by MSD - the product has been facing direct competition since biosimilar versions were launched in 2014/2015 however, and past year, MSD reported sales of the drug fell 24% to $1.8bn as competition drove down pricing.
6. Pfizer to launch second-ever biosimilar in the US

   Oct 19, 2016 | The Village Suntimes

   By Max Garcia
   
   
   Remicade is J&J's biggest selling drug with US sales of about $5 billion a year. That's up from $3.36 billion, or $1.20 per share, in 2015's third quarter.
7. Johnson & Johnson (JNJ) Upgraded to Buy by Vetr Inc.

   Oct 19, 2016 | WKRB

   By Nolan Pearson
   
   
   Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a report issued on Tuesday morning. The brokerage currently has $121.49 price target on the stock.
8. Johnson & Johnson Reports Increase in Sales and Earnings for Third Quarter

   Oct 19, 2016 | Visoin Monday

   Getting a boost from recent new-product launches and a strong core business, Johnson & Johnson (NYSE:JNJ) reported on Tuesday that its worldwide sales rose 4.2 percent to $17.8 billion in the third quarter compared with the year-ago period, while U.S. sales rose at an even stronger pace of 6.7 percent.
9. Johnson & Johnson Q3 numbers top expectations

   Oct 19, 2016 | Pop Herald

   By Kim Silva
   
   
   Up to Monday's close, J&J's shares had gained about 15 percent since the start of the year, compared with a 3.7 percent decline in the S&P 500 healthcare sector. A Exec VP, Finance; CFO at Johnson & Johnson (JNJ) sold shares in a trading activity completed on Tuesday July 26, 2016. The Hedge Fund company now holds 72,615 shares of JNJ which is valued at $8,699,277. Citigroup Inc makes up approx 0.03% of Eqis Capital Management's portfolio.
10. Johnson & Johnson tops Street view as 3Q drug sales surge

    Oct 19, 2016 | New York South East Post

    Operational sales rose 4.3%, with Domestic sales gaining 6.7% and worldwide sales rising 1.5%. Worldwide Pharmaceutical sales gained 9.2% to $8.4 billion.
11. J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales

    Oct 18, 2016 | Zack's Equity Research

    Johnson & Johnson (JNJ - Free Report) reported another strong quarter with both earnings and sales beating expectations. Moreover, the company raised the lower end of its earnings outlook for the year.
12. Pfizer to launch biosimilar version of J&J's Remicade in Nov.

    Oct 18, 2016 | Becker's Hospital Review

    By Mackenzie Bean
    
    
    New York City-based Pfizer will start shipping its biosimilar copy of Johnson & Johnson's best-selling arthritis drug Remicade in November, offering the drug at a 15 percent discount, according to Reuters.
13. Jefferies Group Comments on Johnson & Johnson’s FY2018 Earnings (JNJ)

    Oct 18, 2016 | Web Breaking News

    By Tony Sherman
    
    
    Johnson & Johnson (NYSE:JNJ) – Stock analysts at Jefferies Group lowered their FY2018 earnings estimates for Johnson & Johnson in a report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will earn $7.16 per share for the year, down from their prior forecast of $7.30. Jefferies Group currently has a “Hold” rating and a $115.00 price objective on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.52 EPS.
14. Pfizer’s spoiler on Johnson & Johnson’s earnings rally

    Oct 18, 2016 | Proactive Investors

    By George Matlock
    
    
    The world’s largest healthcare company Johnson & Johnson’s third-quarter earnings per share came in 3 cents higher than analysts’ forecasts. But Pfizer said it will launch a cheaper competing product to J&J's flagship drug Remicade
15. Johnson & Johnson Brushes Off Looming Biosimilar Competition, Posts Solid Results

    Oct 18, 2016 | Wall Street Journal

    By Jonathan Rockoff and Anne Steele
    
    
    Johnson & Johnson on Tuesday sought to reassure investors and analysts that lower-priced competition for one of its top-selling products won’t slow a company that posted slightly better-than-expected results in the third quarter.
16. (UPDATE) Johnson & Johnson Again Buoyed by Pharmaceuticals

    Oct 18, 2016 | Wall Street Journal

    By Anne Steele
    
    
    Johnson & Johnson lifted the low end of its guidance and posted better-than-anticipated results in the latest quarter as the health-care giant’s pharmaceutical business continues to buoy its top line.
17. (UPDATE – 3) Johnson & Johnson tops 3Q Street view but shares decline

    Oct 18, 2016 | Associated Press

    By Linda A. Johnson
    
    
    Johnson & Johnson shares dropped Tuesday, despite the health care bellwether boosting its third-quarter profit 27 percent. Investors apparently are worried about unexpectedly early competition to the company's longtime top seller.
18. J&J says pharma future bright, despite threat to Remicade

    Oct 18, 2016 | Reuters

    By Ransdell Pierson
    
    
    Johnson & Johnson (JNJ.N) on Tuesday reported a better-than-expected quarterly profit and said its phamaceutical business will keep prospering despite the threatened launch of a competitor for its blockbuster Remicade arthritis drug.
19. Pfizer's Remicade Rudeness Shouldn't Faze J&J

    Oct 18, 2016 | Bloomberg

    By Max Nisen
    
    
    The pharma world can be cutthroat as firms jockey for position with competing drugs. But even in that context, Pfizer's decision to announce a late-November launch of its competing version of Johnson & Johnson's best-selling drug Remicade the afternoon before J&J released its third-quarter earnings seems a bit cold.
20. (UPDATE – 2) J&J Falls as Cheaper Competition for Blockbuster Remicade Looms

    Oct 18, 2016 | Bloomberg

    By Jared S Hopkins
    
    
    Johnson & Johnson’s third-quarter profit topped analysts’ estimates as blockbuster drugs such as arthritis treatment Remicade boosted pharmaceuticals sales
21. Johnson & Johnson beat profit and sales expectations, lifts earnings outlook

    Oct 18, 2016 | Market Watch

    By Tomi Kilgore
    
    
    Johnson & Johnson JNJ, +0.26% reported Tuesday third-quarter earnings that rose to $4.27 billion, or $1.53 a share, from $3.36 billion, or $1.20 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.68, beating the FactSet consensus of $1.65. Revenue increased 4.2% to $17.82 billion, above the FactSet consensus of $17.74 billion, as bigger-than-expected increases in pharmaceutical and medical devices sales offset less-than-expected consumer sales. Looking ahead, the drug and consumer products giant lifted its EPS outlook to $6.68 to $6.73 from $6.63 to $6.73, and kept its revenue outlook at $71.5 billion to $72.2 billion. "With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Chief Executive Alex Gorsky. The stock, which was indicated about 1% higher in premarket trade, has climbed 15% year to date through Monday, while the Dow Jones Industrial Average DJIA, -0.29% has gained 3.8%.
22. Johnson & Johnson (JNJ) Releases Earnings Results, Beats Expectations By $0.02 EPS

    Oct 18, 2016 | Market Digest

    By Aaron Hall
    
    
    Johnson & Johnson (JNJ) announced its most recent quarterly financial results on Tuesday, Oct-18-2016. JNJ said it had a profit of $1.68 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $1.66. The company posted revenue of $17820.00 million in the period, compared to analysts expectations of $17744.90 million. JNJ’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS
23. (UPDATE–2) J&J revenue, profit edge past estimates on robust drug sales

    Oct 18, 2016 | Reuters

    By Natalie Grover
    
    
    Johnson & Johnson (JNJ.N), the world's largest maker of healthcare products, reported third-quarter revenue and profit just ahead of Wall Street estimates, fueled by strong sales in its prescription drugs business.
24. J&J prepares for drug price war with Pfizer

    Oct 18, 2016 | Financial Times

    By David Crow
    
    
    Johnson & Johnson set the stage for a price war in one of the most lucrative segments of the pharmaceuticals industry, as it announced its intention to discount its top-selling arthritis drug following the introduction of a cheaper knock-off version.
25. Johnson & Johnson Delivers Another Earnings Beat

    Oct 18, 2016 | Benzinga

    By R. Chandrasekaran
    
    
    Johnson & Johnson JNJ delivered better than expected results for the third quarter, as earnings and revenue came in above the Street estimates.
26. Johnson & Johnson Q3 Profit Tops Estimates; Raises FY16 Adj. EPS Guidance

    Oct 18, 2016 | RTT News

    Johnson & Johnson (JNJ) reported third-quarter net earnings of $4.3 billion or $1.53 per share compared to $3.4 billion or $1.20 per share, prior year. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted earnings per share also increased 12.8%. On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $1.65 for the quarter. Analysts' estimates typically exclude special items.
27. Johnson & Johnson Boosts Outlook as Q3 Earnings Beat Estimates

    Oct 18, 2016 | ETF Daily News

    The New Brunswick, NJ-based company reported adjusted Q3 EPS of $1.68, beating out Wall Street’s expectations of $1.66. Revenue rose 4.2% from last year to $17.82 billion, also eclipsing analysts’ view of $17.74 billion.
28. Trader’s Spotlight- Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | Hot Stocks Point

    By Robert Ebelling
    
    
    Johnson & Johnson’s (JNJ)’s Stock Price Trading Update: Johnson & Johnson’s (JNJ) stock price ended its day with a gain of 0.79% and finalized at the value of $118.49. During its last trading session, Stock traded with the total exchanged volume of 6.94 million shares. The average volume stands around 6.06 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 1.15. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Johnson & Johnson’s (JNJ) is a part of Healthcare sector and belongs to Drug Manufacturers – Major industry.
29. Johnson & Johnson Q3 numbers top expectations

    Oct 18, 2016 | Digital Look

    By Michele Maatouk
    
    
    Johnson & Johnson posted better-than-expected third-quarter numbers on Tuesday and lifted its earnings outlook for the year.
30. J&J raises 2016 profit outlook

    Oct 18, 2016 | USA Today

    By Nathan Borney
    
    
    Health products conglomerate Johnson & Johnsonraised its 2016 profit forecast after beating third-quarter expectations for profit and sales.
31. Johnson & Johnson Earnings Top Estimates on Solid Pharmaceutical Sales

    Oct 18, 2016 | The Street

    By Martin Baccardax
    
    
    Johnson & Johnson (JNJ) beat analysts' expectations with its third-quarter earnings Tuesday as pharmaceutical sales notched a solid advance, offsetting weakness in its consumer products group.
32. Johnson & Johnson’s Q3 numbers top estimates, medical devices biz grows slightly

    Oct 18, 2016 | Mass Device

    By Brad Perriello
    
    
    Third-quarter sales ticked up 4% and profits grew at a double-digit clip forJohnson & Johnson (NYSE:JNJ), the company said today, and its medical devices business posted sales growth of just more than 1%.
33. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

    Oct 18, 2016 | Financial Market News

    By Don March
    
    
    Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion
34. Without Drugs, Johnson & Johnson Has Nothing (JNJ)

    Oct 18, 2016 | Investor Place

    By Dana Blankenhorn
    
    
    Johnson & Johnson (NYSE:JNJ) shareholders are waking up with a shrug today. JNJ stock is slightly off after the thinnest of earnings beats, with the save coming from the company’s pharmaceutical business.
35. Johnson & Johnson (JNJ) Beats on Q3 Earnings, Revenues

    Oct 18, 2016 | Zack’s Equity Research

    Johnson & Johnson (JNJ - Analyst Report) ), the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
36. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results

    Oct 18, 2016 | The Cerbat Gem

    By Scott Moore
    
    
    Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday. The company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.66 by $0.02. The business had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%.
37. Worth Watching Stock: Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | News Oracle

    By Adam Smith
    
    
    Johnson & Johnson (NYSE:JNJ) will report its next earnings on 18-Oct-16. The company reported the earnings of $1.74/Share in the last quarter where the estimated EPS by analysts was $1.68/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 3.6%.
38. Johnson & Johnson (JNJ) Releases FY16 Earnings Guidance

    Oct 18, 2016 | Daily Political

    By Jeff Wilder
    
    
    Johnson & Johnson (NYSE:JNJ) updated its FY16 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $6.68-6.73 for the period, compared to the Thomson Reuters consensus estimate of $6.69. The company issued revenue guidance of $71.5-72.2 billion, compared to the consensus revenue estimate of $72.14 billion.
39. What To Make Of Johnson & Johnson At $118 In The Wake Of Q3 Results

    Oct 18, 2016 | Seeking Alpha

    By Alessandro Pasetti
    
    
    The third-quarter results of Johnson & Johnson (NYSE:JNJ), which were released today, suggest that shareholders are in a sweet spot. Or are they? Before delving into third-quarter figures, it's worth looking at the headline numbers in the first half of the year.
40. Johnson & Johnson Remains Flat Despite Earnings Beat

    Oct 18, 2016 | 24/7 Wall Street

    By Chris Lange
    
    
    Johnson & Johnson (NYSE: JNJ) released its third-quarter earnings report before the markets opened on Tuesday. The company said that it had $1.68 in earnings per share (EPS) and $17.8 billion in revenue. The third-quarter from last year reportedly had $1.49 in EPS and revenue of $17.1 billion. Thomson Reuters consensus estimates had called for EPS of $1.65 and $17.74 billion in revenue.
41. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

    Oct 18, 2016 | Community Financial News

    By Trent Williams
    
    
    Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.66 by $0.02. The company earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%.
42. Johnson & Johnson (JNJ) Beats Estimates, Reports $1.68 EPS

    Oct 18, 2016 | Economic Calendar

    By Paul Rosenberg
    
    
    Johnson & Johnson (NYSE:JNJ) reported third-quarter results this morning, topping analyst estimates. The company reported adjusted earnings per share of $1.68 on $17.8 billion in revenues. This was an increase in revenues of 4.2% from the same quarter a year-ago. Analysts on average were looking for $1.66 EPS on $17.7 billion in revenues.
43. Stay calm, investors. J&J has a 'readiness plan' in place for Remicade biosim launch

    Oct 18, 2016 | FiercePharma

    By Arelen Weintraub
    
    
    Just yesterday, one of the biggest potential threats to Johnson & Johnson’s ($JNJ) top line moved closer to reality as Pfizer ($PFE) announced it will begin shipping a biosimilar version of J&J’s blockbuster Remicade in late November. But executives of J&J, who had been insisting they wouldn’t face biosimilar competition this year, weren’t fazed during the company’s third-quarter earnings release today, even though Remicade’s stand-out performance clearly raises questions about how healthy the top line will be if it takes a hit from Pfizer’s rival product.
44. The Statistics Don’t Lie: Johnson & Johnson (NYSE:JNJ) Earnings Preview

    Oct 18, 2016 | Voice Registrar

    By Claudia Dawson
    
    
    Johnson & Johnson (NYSE:JNJ) got boosted by 0.79 per cent through the trading floor to reach at $118.49 as its next quarterly earnings report date is October 18, 2016. JNJ stock is keeping its price in the $117.5 to $118.55 range before earnings are released. Let’s take a deeper look at the December 2016 earnings forecast, particularly something that investors should watch closely when picking stocks. Earnings per share for the most recently closed financial statements is expected to come in at $1.58/share with $18.39B in revenue.
45. J&J Sees No Obstacles From Absence of Tax Reform

    Oct 18, 2016 | The Street

    By Sarah Pringle
    
    
    Johnson & Johnson's (JNJ) CFO Dominic Caruso told investors on a Tuesday morning conference call that its future dealmaking possibilities don't rely on the passage of international tax reform, though he did say he views there being more bipartisan support for such legislation than in the past. At the same time, the exec voiced his opposition to the California drug pricing ballot measure known as Prop 61.
46. Johnson & Johnson Under Heavy Pressure

    Oct 18, 2016 | The Street

    By Gary Morrow
    
    
    Shares of Johnson & Johnson (JNJ) were getting hit hard Tuesday morning despite a strong earnings report before the bell. The stock is off 2.3% on heavy trade and is taking out a very solid support zone in the process. This nasty breakdown has further to go.
47. Competition Is Concerning for Johnson & Johnson

    Oct 18, 2016 | Morningstar

    By Damien Conoves
    
    
    Johnson & Johnson (JNJ) reported second-quarter results slightly ahead of both our and consensus expectations, but we don’t expect any major changes to our $112 fair value estimate, suggesting the stock looks slightly overvalued. We continue to believe the market is not incorporating enough declines on several complex drugs, including Concerta (2017-18 expected generic competition), Risperdal Consta (2017), Velcade (2016-19), Remicade (2016-18), and Invega Sustenna (2018). While the majority of these drugs will face slower declines then typical small molecules, we project more rapid declines than consensus. For the company’s largest drug, Remicade, we expect 2020 sales of below $4 billion relative to consensus expectations of $5.3 billion. While the magnitude of these losses is concerning, JNJ’s breadth of businesses helps reinforce its moat during times of excessive patent losses.
48. Stock Jumping Abnormally High: Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | Facts Reporter

    By Jay Jacobs
    
    
    Johnson & Johnson (NYSE:JNJ) belonging to the Medical sector has surged 0.79% and closed its last trading session at $118.49.
49. Pfizer loads up for Remicade biosim launch, with $4.5B J&J brand in its sights

    Oct 18, 2016 | FiercePharma

    By Eric Sagonowsky
    
    
    Pfizer’s U.S. biosimilar assault on Johnson & Johnson’s star autoimmune med Remicade is set for go. Late Monday, Pfizer said it’ll begin shipping its Remicade biosimilar, Inflectra, late next month.
50. Johnson & Johnson Reported Better-than-Expected Earnings Boosted by Pharmaceuticals

    Oct 18, 2016 | Financial Buzz

    Johnson & Johnson (NYSE:JNJ) reported its financial results of the third quarter of 2016, announcing better-than-anticipated sales and earnings, and raising the forecasts for the full-year 2016.
51. Johnson & Johnson (JNJ) 'Tracking Higher Expectations,' CFO Caruso Says

    Oct 18, 2016 | The Street

    By Giovanni Bruno
    
    
    Johnson & Johnson (JNJ) reported better-than-expected 2016 third-quarter earnings results before the market open on Tuesday. The healthcare products company posted earnings of $1.68 per share on revenue of $17.8 billion. Analysts were projecting earnings of $1.65 per share on revenue of $17.74 billion.
52. Pfizer to launch cheaper version of J&J immune drug Remicade

    Oct 18, 2016 | The Village Suntimes

    By Jay Jacobs
    
    
    Inflectra, okayed by the U.S. Food and Drug Administration in April, was the second biosimilar to gain U.S. approval and the first copycat version of Johnson & Johnson's blockbuster anti-inflammatory drug Remicade.
53. Why Johnson & Johnson is Tanking

    Oct 18, 2016 | Barron’s

    By Ben Levisohn
    
    
    Johnson & Johnson (JNJ) did everything you could ask a company to do when it reported its third-quarter financial results today. It beat earnings forecasts; its sales easily topped the Street consensus; and it increased its guidance. Still, shares of Johnson & Johnson have dropped more than 2%. What gives? Leerink’s Danielle Antalffy explains:
54. Pharma Boosts Johnson & Johnson Despite Falling Consumer Sales

    Oct 18, 2016 | Motley Fool

    By Dan Caplinger
    
    
    It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE:JNJ) isn't its most important business segment. Indeed, recently, consumer products have been the laggard for the healthcare conglomerate, and strength in the pharmaceutical business has been the key driver of overall growth for J&J. Coming into Tuesday's third-quarter financial report, J&J investors fully expected that those trends would continue, creating modest sales growth that would translate into bottom-line success. Johnson & Johnson's results were even stronger than anticipated, giving shareholders comfort that the healthcare giant is still moving forward. Let's take a closer look at Johnson & Johnson's latest results and what lies ahead for the company.J&J rides the pharma train higher
55. Pay Close Attention to These Analyst Ratings: Johnson & Johnson (NYSE: JNJ), Church & Dwight Co. Inc. (NYSE: CHD)

    Oct 18, 2016 | Voice Registrar

    By Lewis Gonzalez
    
    
    Johnson & Johnson (NYSE:JNJ) went up 0.79% during trading on 10/17/2016, with the company’s shares hitting the price near $118.49. The stock had a trading capacity of 6.94M shares. The firm has a SMA 50 (Simple Moving Average) of $118.72 and a SMA 200-(Simple Moving Average) of $117.37. This appreciation has taken its market valuation to 326.10B. Shares registered one year high at $125.23 and the one year low of $92.21.
56. Investment Research Analysts Opinion: Johnson & Johnson (NYSE:JNJ), Mylan N.V. (NASDAQ:MYL)

    Oct 18, 2016 | The Wellesley News

    By Rodolfo Page
    
    
    At the most recent close, Johnson & Johnson (NYSE:JNJ) tinted gains of +0.79% (+0.93 points) to US$118.49. The volume of 6.94 Million shares climbed up over an trading activity of 6.06 Million shares. EPS ratio determined by looking at last 12 month figures is 5.37. Over the same time span, the stock marked US$126.07 as its best level and the lowest price reached was US$94.28. The corporation has a market cap of US$326.1 Billion.

Television Coverage

57. Squawk Box

    Oct 18, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24580931?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (03:37)
58. Bloomberg Daybreak

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24581068?token=1f262742-0cd0-43e0-a677-9b779fc19bdb (06:02)
59. Squawk Box

    Oct 18, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24580788?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (00:23)
60. Bloomberg Surveillance

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24580802?token=1f262742-0cd0-43e0-a677-9b779fc19bdb (00:22)
61. Bloomberg Surveillance

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24580809?token=1f262742-0cd0-43e0-a677-9b779fc19bdb (00:39)
62. Bloomberg Daybreak: Americas

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24581302?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (00:28)
63. Squawk Box

    Oct 18, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24581329?token=1f262742-0cd0-43e0-a677-9b779fc19bdb (00:44)
64. Bloomberg Daybreak: Americas

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24582540?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (00:23)
65. Bloomberg Radio Clip

    Oct 18, 2016 | Bloomberg

    By Bloomberg Markets (Radio)
    
    
    http://app.criticalmention.com/app/#clip/view/24584556?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (04:31)
66. Bloomberg Markets: European Close

    Oct 18, 2016 | BLOOM-TV

    View clip here: http://app.criticalmention.com/app/#clip/view/24583876?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (00:20)
67. Power Lunch

    Oct 18, 2016 | CNBC

    View clip here: http://app.criticalmention.com/app/#clip/view/24584682?token=74ea5693-5128-42c8-bc42-3b28fe421fd3 (00:13)
68. After the Bell Clip

    Oct 19, 2016 | Fox Business News

    http://app.criticalmention.com/app/#clip/view/24586945?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e (00:22)
69. Fast Money

    Oct 19, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24593847?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e (01:19)
70. Nightly Business Report

    | FX

    http://app.criticalmention.com/app/#clip/view/24594057?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e (01:00)
71. Global Business

    Oct 19, 2016 | CCTV

    http://app.criticalmention.com/app/#clip/view/24594142?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e (00:15)
72. Squawk on the Street

    Oct 19, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24594183?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e (00:16)

Traditional Coverage

1. Key Takeaways from JNJ’s Q3 Call: Remicade, Pipeline, Acquisitions

   Oct 19, 2016 | Stock Rants

   Healthcare giant and industry bellwether Johnson & Johnson JNJ reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations (Read more: J&J Outshines in Q3 Earnings on Strong Pharma Sales). However, shares were down 2.6% on concerns regarding future growth prospects of the company’s blockbuster top-selling drug, Remicade.

   Here’s a close look at some important takeaways from the company’s third quarter conference call.
   
   Remicade Biosimilar Round the Corner
   
   Needless to say, the most discussed topic on the call was Pfizer, Inc.’s PFE recent announcement that it will be launching its biosimilar version of J&J’s multi-billion dollar drug, Remicade, in late November. Inflectra, Pfizer’s biosimilar, will be priced at a 15% discount to the current wholesaler acquisition cost (WAC) of Remicade.
   
   J&J expects the rate of penetration of a biosimilar entrant to be modest. Here’s why: with Inflectra not being interchangeable, patients who are stable on Remicade are highly unlikely to switch to a biosimilar – that would be about 70% of the patients. The significant long-term safety data on Remicade, strong advocacy from patients and clear physician preference should also work in Remicade’s favor.
   
   Secondly, J&J said that it has a strong patient assistance program in place which could prove to be a market differentiator. Moreover, the company is ready to compete in all channels to provide patients with the most affordable option in every situation.
   
   J&J also pointed out that in Canada, Australia and Brazil where biosimilar Remicade is already available, the company has maintained more than 90% volume share.
   
   Meanwhile, the company intends to appeal a court ruling in August related to the ‘471 patent. Moreover, a trial related to the media patent is scheduled for mid-Feb 2017.
   
   Pipeline on Track
   
   Last year, J&J had announced that it intends to seek approval for more than 10 new products between 2015 and 2019. The company said that each of these products has blockbuster potential and it would be targeting more than 40 line extensions of existing and new drugs as well. This target was reiterated on the company’s third quarter call with the company providing an update on important pipeline candidates.
   
   While sirukumab, a key candidate in the immunology pipeline, has been filed for approval in the U.S. and EU for a rheumatoid arthritis indication, the company expects to submit the regulatory application for guselkumab for psoriasis by year-end. Plans are also on to move guselkumab into late-stage development for psoriatic arthritis.
   
   Within oncology, J&J has a broad clinical development program for apalutamide in both pre-metastatic and metastatic prostate cancer. The company is also evaluating it in combination with Zytiga and PARP inhibitor, niraparib. Niraparib is in phase II studies with regulatory filings expected in 2019.
   
   In the neurology segment, esketamine (treatment-resistant depression) is already in late-stage development. Meanwhile, the company is moving a 3DAA combination of Olysio, AL-335 and odalasvir into late-stage studies for hepatitis C virus infection.
   
   Acquisition Plans?
   
   J&J, which will be completing its acquisition of Abbott Medical Optics in the first quarter of 2017, was asked about its acquisition plans. The company has about $40 billion in cash and marketable securities. The company said that it has specific areas of focus in the Consumer segment with the focus mainly on international growth specifically emerging markets, over-the-counter medications and the beauty space particularly in Asia. Within the Medical Devices segment, J&J said that it continues to look for bolt-on acquisitions in orthopedics and general surgery. In the cardiovascular segment, although certain areas like structural heart look attractive, the company was pretty clear about being disciplined from a valuation aspect.
   
   Where Pharma is concerned, J&J will most likely use an “acquisition type” strategy instead of a licensing strategy if it decides to add another major therapeutic area to its existing five major therapeutic areas.
   
   Our Take
   
   Though the upcoming entry of Inflectra will remain a source of concern and does bring in a certain element of uncertainty regarding Pharma segment sales, J&J should be able to retain share as the 15% discount offered by Pfizer may not really end up in huge patient switches especially with the product not being interchangeable. Meanwhile, J&J’s evolving product mix should drive growth in the face of biosimilar competition and market dynamics.
   

   Return to headline | Return to top

2. Stocks to Keep Your Eyes on Johnson & Johnson (NYSE:JNJ), STMicroelectronics NV (ADR) (NYSE:STM)

   Oct 19, 2016 | Wall Street 24

   By David Williams

   On Tuesday, Johnson & Johnson (NYSE:JNJ)stock opened its trade at $117.38 and after floating in a range of $115.16 to $118.48, settled at $115.41. The stock lost -2.60% in total of its share price. The stock’s 52-week range is $94.28 – $126.07.

   Johnson & Johnson (JNJ) declared sales of $17.8 billion for the third quarter of 2016, a boost of 4.2% as contrast to the third quarter of 2015. Operational sales results raised 4.3% and the negative impact of currency was 0.1%. Domestic sales raised 6.7%. International sales raised 1.5%, reflecting operational growth of 1.7% and a negative currency impact of 0.2%. Apart From the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales raised 5.9%, domestic sales raised 7.3% and international sales raised 4.2%.* Operations in Venezuela negatively influenced worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.
   

   Net earnings and diluted earnings per share for the third quarter of 2016 were $4.3 billion and $1.53, respectively. Third quarter 2016 net earnings included after-tax intangible amortization expense of about $0.2 billion and a charge for after-tax special items of about $0.2 billion. Third quarter 2015 net earnings included after-tax intangible amortization expense of about $0.4 billion and a charge for after-tax special items of about $0.4 billion. Apart From after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as contrast to the same period in 2015.* On an operational basis, adjusted diluted earnings per share also raised 12.8%.* A reconciliation of non-GAAP financial measures is included as an accompanying plan.

   JNJ stock’s price is now -7.84% down from its 52-week high and +25.01% up from its 52-week low. Beta factor of the stock stands at 0.62. Beta factor is used to measure the volatility of the stock. The stock remained 1.45% volatile for the week and 1.12% for the month.

   Taking a look into the performance of JNJ stock, investor will come to know that the weekly performance for this stock is valued at -1.90%, resulting in a performance for the month at -1.91%. Therefore, the stated figure displays a quarterly performance of -7.16% and year to date performance of 14.74%.

   Looking into the profitability ratios of JNJ stock, investor will find its ROE, ROA, ROI standing at 20.90%, 11.10% and 14.70%, respectively.

   Shares of STMicroelectronics NV (ADR) (NYSE:STM) inclined 1.85% to $8.26. Stock exchanged hands with the total volume of 4.15 Million shares, as contrast to its average volume of 2.62 Million shares. The 52-week range of the share price is from $5.11 – $8.41. For trailing twelve months, EPS value for the stock is $0.08. STMicroelectronics (STM.PA), a global semiconductor leader serving customers across the spectrum of electronics applications, recently declared that its LSM6DSM 6-axis Inertial Measurement Unit (IMU) has earned certification for use in next-generation mobile devices running Google Daydream, a high-performance virtual-reality platform, and Tango, a platform that maps 3D space and facilitates it to be overlaid with virtual objects.

   Declared at the Google I/O Developer Conference 2016, Daydream is being built into the newest generation of smartphones and other mobile devices and will operate together with a controller and a viewer to provide an amazing immersive virtual reality experience for exploring new worlds, enjoying entertainment with your own personal cinema and gaming.

   Return to headline | Return to top

3. Gavekal Capital Lowers stake in Johnson & Johnson (JNJ)

   Oct 19, 2016 | Founders Daily

   By Jim Swaby

   Johnson & Johnson (JNJ) : Gavekal Capital reduced its stake in Johnson & Johnson by 35.86% during the most recent quarter end. The investment management company now holds a total of 73,782 shares of Johnson & Johnson which is valued at $8,673,812 after selling 41,259 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.Johnson & Johnson makes up approximately 2.96% of Gavekal Capital’s portfolio.

   Other Hedge Funds, Including , Starfire Investment Advisers boosted its stake in JNJ in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 4,973 shares of Johnson & Johnson which is valued at $584,626. Johnson & Johnson makes up approx 0.40% of Starfire Investment Advisers’s portfolio.Genesee Valley Trust Co reduced its stake in JNJ by selling 27 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 21,065 shares of JNJ which is valued at $2,478,087. Johnson & Johnson makes up approx 1.60% of Genesee Valley Trust Co’s portfolio.Bristol John W Co Inc Ny reduced its stake in JNJ by selling 31,482 shares or 1.66% in the most recent quarter. The Hedge Fund company now holds 1,866,081 shares of JNJ which is valued at $223,556,504. Johnson & Johnson makes up approx 6.13% of Bristol John W Co Inc Ny’s portfolio.Cardinal Capital Management reduced its stake in JNJ by selling 2,012 shares or 1.85% in the most recent quarter. The Hedge Fund company now holds 106,737 shares of JNJ which is valued at $12,720,916. Johnson & Johnson makes up approx 1.44% of Cardinal Capital Management’s portfolio.Harbour Capital Advisors reduced its stake in JNJ by selling 175 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 18,876 shares of JNJ which is valued at $2,249,642. Johnson & Johnson makes up approx 1.21% of Harbour Capital Advisors’s portfolio.

   Johnson & Johnson closed down -0.7 points or -0.59% at $117.56 with 56,40,519 shares getting traded on Friday. Post opening the session at $118.5, the shares hit an intraday low of $117.56 and an intraday high of $118.8 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

   On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Oct 18, 2016. Analyst had a consensus of $1.66. The company had revenue of $17820.00 million for the quarter, compared to analysts expectations of $17744.90 million. The company’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS.

   Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .

   Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

   Return to headline | Return to top

4. J&J Sees Growth In 2017, Looks For Bolt-On Deals, Launches Texas Startup Accelerator

   Oct 19, 2016 | Med Device Online

   By Jof Enriquezq

   Johnson & Johnson (J&J) is expecting above-market growth in 2017 for its medical device business, and is looking for bolt-on acquisitions to further solidify its already strong presence in the orthopedics, general surgery, and cardiovascular product segments.

   J&J CFO Dominic J. Caruso says robust growth in the medical device business will continue despite a slowdown, with fewer hospital admissions and hospital surgical procedures during the summer months. He says a rebound in the number of hospital procedures, beginning in September, is expected to drive the trajectory upward into next year.

   "Going into 2017, I expressed confidence in our Medical Devices business growing faster, and quite frankly, you know we have a plan for that business to return to growth at above market for the Medical Devices sector and it's continuing to improve. What gives me confidence there is that the area that we focused the most on, the growth platforms and priority platforms, just this quarter they grew at 9 percent, and within those, three of those in particular, electrophysiology, energy and endocutters, each grew at double-digit growth. So we obviously have very robust growth coming in the priority platforms, which we expect to continue and drive us to above market growth in 2017," Caruso told analysts during the earnings call.

   J&J reported sales of $17.8 billion for the third quarter of 2016, an increase of 4.2 percent, compared to the third quarter of 2015. The figures were buoyed by improvement in margins for the Medical Worldwide Device business, which posted sales of $6.2 billion for the third quarter of 2016, representing an increase of 1.1 percent versus the prior year. Pharmaceutical worldwide sales rose strongly by 9 percent over 2015 levels, to $8.4 billion.

   The medical device business was driven by 16 percent worldwide growth in Electrophysiology (within Cardiovascular), on account of the growing number of atrial fibrillation procedures performed. Orthopedics sales growth was driven by joint reconstruction and U.S. trauma, particularly from continued success of the TFNA nailing system in trauma, the ATTUNE platform in knees, and the CORAIL primary stem in hips. Within Advanced Surgery, endocutters increased 14 percent, energy rose 10 percent, and biosurgicals grew 7 percent. The Hospital Medical Devices business expanded 4 percent in the third quarter. Vision Care sales were up by 5.5 percent worldwide due to new product launches.

   J&J acquired Abbott's eye business in September, and Caruso feels "excited about Abbott Medical Optics' strong and differentiated surgical ophthalmic portfolio, particularly in cataract surgery" and, along with its world-leading ACUVUE contact lens business, should "help J&J become a broad-based leader in vision care."

   For the medical device business going forward, Caruso said the company is "looking for additional bolt-on acquisitions" in orthopedics and general surgery (like the acquisition of biotech startup NeuWave Medical), as well as certain cardiovascular areas, such as structural heart, but will be "very disciplined about doing a transaction where the valuation seem pretty high."

   J&J executives credit the company's continued growth to R&D investments and commercial productive innovation. Related, the same day J&J announced its third quarter results, the company said it will open its latest startup accelerator, a partnership with Texas Medical Center (TMC) to develop and commercialize breakthrough medical devices.

   "Working together, we are creating a globally competitive innovation ecosystem here, and the new Center for Device Innovation @ TMC will enable us to expeditiously bring discovery and innovation to fruition, directly improving the health of patients," said Robert C. Robbins, M.D., President and CEO, TMC, in a news release.

   Return to headline | Return to top

5. J&J shares lose ground on fears of Pfizer's answer to Remicade

   Oct 19, 2016 | The Village Suntimes

   By Jay Jacobs

   In Europe - where Remicade is marketed by MSD - the product has been facing direct competition since biosimilar versions were launched in 2014/2015 however, and past year, MSD reported sales of the drug fell 24% to $1.8bn as competition drove down pricing. 

   The Pfizer drug, Inflectra, is already available in Europe and other overseas markets, and was approved by US health regulator earlier this year, but a protracted patent battle impacted its launch. 

   In addition, management stated on the Q3 call that it expects growth in 2017 to be similar to 2016 minus the impact from biosimilar Remicade. It is approved for the treatment of: adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn's disease who have had an inadequate response to conventional therapy; adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy; and moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis. But Edward Jones analyst Ashtyn Evans predicted J&J's annual pharmaceutical sales will grow in the "high single digit" percentage range over the next 3 to 5 years, despite Remicade's decline, as newer drugs for inflammatory conditions and cancer continue post strong sales.

   Pfizer, Inc., will begin shipment of Inflectra (infliximab-dyyb) for injection, a biosimilar of blockbuster arthritis drug Remicade (infliximab, Janssen Biotech), to USA wholesalers in late November 2016.

   As it is not possible to produce exact copies of biotech drugs made from living cells, the cheaper versions - referred to as biosames rather than generics - are meant to provide cost savings compared with pricey biologic medicines.

   J&J stated in an emailed statement that it considers any sales by Pfizer of a Remicade biosame to be an "at risk launch".

   Inflectra will be priced 15 percent less than Remicade's roughly $2,600 monthly list price and is sure to cut into Remicade sales, as biosimlars have already done in Europe and Canada. That could entitle the company to triple damages if Pfizer is found in court to have infringed Remicade patents. The company retained the upper end at $6.73 per share. Pharmaceutical sales were up 9% to $8.4 billion, buoyed by higher sales of Remicade, Stelara (ustekinemab) and Imbruvica (ibrutinib).

   Global device sales inched up 1.1 percent to $6.16 billion in the third quarter, while consumer product sales fell about 1.6 percent to $3.26 billion.

   J&J, the first major USA drugmaker to announce quarterly earnings, maintained its revenue forecast for the year. The company's net earnings rose to US$4.27 billion, or US$1.53 per share, in the third quarter, from US$3.36 billion, or US$1.20 per share, a year earlier.

   Adjusted for amortization costs and other one-time items, earnings amounted to $1.68 per share. 
   

   Return to headline | Return to top

6. Pfizer to launch second-ever biosimilar in the US

   Oct 19, 2016 | The Village Suntimes

   By Max Garcia

   Remicade is J&J's biggest selling drug with US sales of about $5 billion a year. That's up from $3.36 billion, or $1.20 per share, in 2015's third quarter.

   Looking ahead, J&J lifted the low end of its financial guidance for the year. 

   Adjusted for amortization costs and other one-time items, earnings amounted to $1.68 per share. Pfizer Inc (N:) said on Monday it would begin shipping its biosimilar version of Remicade in late November at a 15 percent discount to current wholesale prices. According to a report on the Wall Street Journal's website, Remicade, which was first approved for sale in the United States in 1998, is J&J's largest product by sales. J&J said in July its forecast for Remicade had assumed no competition from a biosimilar in the United States this year. USA sales of Remicade jumped 9.4 per cent to $1.22 billion. Yet J&J officials sought to push back on concerns about the impact, especially in the near-term. The invasion of multiple therapeutic markets in the USA from the biosimilars is posing severe threat to the blockbuster drugs of giant companies, as they are working on legal fight for the patent protection as well as label expansion of the drugs in order to maintain their revenue traction. J&J also detailed how new uses for existing medicines and drug launches through 2019 could offset any sales losses and provide new revenue growth. "We plan to continue to grow our pharmaceuticals business in the face of biosimilar competition", including in the treatment of immunology diseases like the ones treated by Remicade, Mr. Duato said in an interview. It retained the upper end at $6.73 per share. It repeated its revenue forecast of $71.5 billion to $72.2 billion. Xarelto, for preventing strokes and heart attacks, saw sales jump 15 percent to $529 million in the quarter, while sales of biologic psoriasis drug Stelara soared 33 percent to $814 million and sales of new leukemia and lymphoma treatment Imbruvica almost doubled to $349 million. Global medical device sales rose 1.1 percent to US$6.16 billion in the quarter, while consumer product sales fell 1.6 percent to US$3.26 billion. TheVillagesSuntimes http://thevillagessuntimes.com/2016/10/19/pfizer-to-launch-second-ever-biosimilar-in-the-us/
   

   Return to headline | Return to top

7. Johnson & Johnson (JNJ) Upgraded to Buy by Vetr Inc.

   Oct 19, 2016 | WKRB

   By Nolan Pearson

   Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ)from a hold rating to a buy rating in a report issued on Tuesday morning. The brokerage currently has $121.49 price target on the stock.

   JNJ has been the subject of a number of other research reports. Zacks Investment Research cut shares of Johnson & Johnson from a hold rating to a sell rating in a research note on Wednesday, September 28th. Leerink Swann restated a buy rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. BTIG Research restated a neutral rating on shares of Johnson & Johnson in a research note on Thursday, August 25th. Deutsche Bank AG restated a buy rating and issued a $142.00 price objective on shares of Johnson & Johnson in a research note on Friday, August 19th. Finally, Barclays PLC restated an overweight rating and issued a $125.00 price objective (up previously from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $120.12.

   Shares of Johnson & Johnson (NYSE:JNJ) opened at 115.41 on Tuesday. The firm has a market capitalization of $315.75 billion, a price-to-earnings ratio of 21.51 and a beta of 0.62. The stock has a 50 day moving average of $118.58 and a 200-day moving average of $117.61. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07.

   Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.65 by $0.03. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The company earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same quarter in the prior year, the company posted $1.49 EPS. The business’s revenue was up 4.2% on a year-over-year basis. Analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current year.

   In other news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

   Large investors have recently modified their holdings of the company. Americafirst Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $101,000. Tuttle Tactical Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. raised its stake in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. raised its stake in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. purchased a new stake in Johnson & Johnson during the second quarter valued at $127,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

   Johnson & Johnson Company Profile

   Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

   Return to headline | Return to top

8. Johnson & Johnson Reports Increase in Sales and Earnings for Third Quarter

   Oct 19, 2016 | Visoin Monday

   Getting a boost from recent new-product launches and a strong core business, Johnson & Johnson (NYSE:JNJ) reported on Tuesday that its worldwide sales rose 4.2 percent to $17.8 billion in the third quarter compared with the year-ago period, while U.S. sales rose at an even stronger pace of 6.7 percent. 

   J&J also reported net income of $4.27 billion for the recent quarter. This compared with $3.36 billion in the year-ago quarter. 
   
   J&J chairman and chief executive officer Alex Gorsky said the strong results “reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our pharmaceuticals business.”
   
   He added, “With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion.”
   
   In its vision care group, J&J reported worldwide sales increased 8.2 percent to $739 million in the third quarter, and on an operational basis (excluding the impact of currency fluctuations) the increase was 5.5 percent for the quarter. The company noted that within the U.S. market vision care volume growth was “partially offset by prior period inventory build for [Acuvue] Oasys 1-Day” contact lenses. J&J also noted that strong results by Acuvue contact lenses helped drive the performance in vision care business.
   
   The pharmaceutical sales group also registered high single-digit sales gains. Worldwide drug sales rose 9.2 percent to $8.4 billion, while on an operational basis the increase was 9.0 percent. U.S. pharmaceutical sales increased 11.8 percent in the quarter, while international sales increased 5.4 percent. 
   
   J&J noted that, excluding the net impact of acquisitions, divestitures and hepatitis C sales, worldwide pharmaceutical sales increased 10.7 percent and domestic sales increased 13.0 percent on an operational basis.
   
   The company maintained its sales guidance for 2016 of $71.5 billion to $72.2 billion. During the third quarter, J&J announced a definitive agreement to acquire Abbott Medical Optics, a subsidiary of Abbott Laboratories, for $4.325 billion in cash.
   

   Return to headline | Return to top

9. Johnson & Johnson Q3 numbers top expectations

   Oct 19, 2016 | Pop Herald

   By Kim Silva

   Up to Monday's close, J&J's shares had gained about 15 percent since the start of the year, compared with a 3.7 percent decline in the S&P 500 healthcare sector. A Exec VP, Finance; CFO at Johnson & Johnson (JNJ) sold shares in a trading activity completed on Tuesday July 26, 2016. The Hedge Fund company now holds 72,615 shares of JNJ which is valued at $8,699,277. Citigroup Inc makes up approx 0.03% of Eqis Capital Management's portfolio. 

   Analysts on average had expected a profit of $1.66 per share and revenue of $17.74 billion, according to Thomson Reuters I/B/E/S.

   In midday trading, J&J shares fell $2.36, or 2 percent, to $116.13, as the broader markets rose. Johnson & Johnson topped analysts' earnings estimates for the third quarter as the health care products company's sales rose more than 4 percent from the year-earlier period, it said Tuesday.

   Johnson & Johnson (NYSE:JNJ), with -1.09% losses in previous 5 sessions, is under coverage of 24 analysts who collectively assign a hold rating on stock.

   However, the maker of a variety of products from Tylenol to Band-Aid bandages to Acuvue contact lenses raised the lower end of its adjusted profit range to $6.68 per share from $6.63.

   "With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the (Food and Drug Administration), we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion", Chief Executive Alex Gorsky said in a statement.

   Many Wall Street Analysts have commented on Johnson & Johnson.

   Insiders at the company look pessimistic about the outlook as they seem to offload shares while they have 17.8 jumped so far this year.

   Citigroup Inc. (Citi) is a financial services holding company whose businesses provide consumers corporations governments and institutions with financial products and services including consumer banking and credit corporate and investment banking securities brokerage trade and securities services and wealth management.

   The New Jersey-based company is restructuring its medical device business to focus on areas such as artificial knees and devices for trauma surgery. The Company's subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. But upcoming generic Remicade competition in the US - with Pfizer (PFE) announcing yesterday that it will launch at risk in late November - does add some uncertainty to the 2017 outlook and sustainability of this mid-single-digit growth profile going forward. 

   Return to headline | Return to top

10. Johnson & Johnson tops Street view as 3Q drug sales surge

    Oct 19, 2016 | New York South East Post

    Operational sales rose 4.3%, with Domestic sales gaining 6.7% and worldwide sales rising 1.5%. Worldwide Pharmaceutical sales gained 9.2% to $8.4 billion.
    

    Many analysts didn't expect that competition until 2018 because Pfizer and J&J are still fighting in the courts over whether the US patent protecting Remicade's monopoly is still valid, said Edward Jones analyst Ashtyn Evans.

    Rival Pfizer Inc. announced Monday that in late November it will launch a cheaper rival, a near-copy called a biosimilar, in the USA under the name Inflectra. For the reporting quarter, equity analysts expect the stock to deliver $1.65 in earnings per share (EPS).

    Investors are "beginning to price in the competition" to Remicade, driving down J&J's price, Evans said.

    Remicade, an injected biologic drug for treating rheumatoid arthritis, psoriasis, Crohn's disease and colitis, brought in $5.34 billion in the first three quarters and is one of the world's top-selling medicines.

    Inflectra will be priced 15 percent less than Remicade's roughly $2,600 monthly list price and is sure to cut into Remicade sales, as biosimlars have already done in Europe and Canada. Analysts are now looking for $6.69 per share for the year. Other segments of the company are not as strong as pharmaceuticals business.

    Shares closed Monday at $118.49, with a consensus analyst price target of $124.50 and a 52-week trading range of $94.28 to $126.07.

    Looking more closely at Johnson & Johnson's product lines, the company said that Listerine oral care and Aveeno skin care products were among the biggest positive contributors on the consumer front, although lower inventory levels in the US held back growth.

    Shares of Johnson & Johnson have dropped 2.1% to $115.97 at 11:38 a.m. today, while Pfizer has risen 0.9% to $32.79.

    Sales of autoimmune drug Remicade, J&J's biggest product, rose 10.5 percent to $1.78 billion.

    The New Brunswick-based giant said in a news release that adjusted diluted earnings came in at $1.68 per share for the quarter, up 12.8 percent from the same quarter in 2015. Xarelto, for preventing strokes and heart attacks, saw sales jump 15 percent to $529 million in the quarter, while sales of biologic psoriasis drug Stelara soared 33 percent to $814 million and sales of new leukemia and lymphoma treatment Imbruvica almost doubled to $349 million. Gains for medical devices were much smaller, rising 1.1% from year-ago levels, and the consumer division actually lost ground on the sales front with a 1.6% decline.

    Net earnings for the quarter were $4.3 billion, with diluted EPS of $1.53, the company said, while adjusted net earnings were $4.7 billion.

    The company retained the upper end at $6.73 per share, and also backed its revenue forecast for the year.
    

    Return to headline | Return to top

11. J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales

    Oct 18, 2016 | Zack's Equity Research

    Johnson & Johnson (JNJ - Free Report) reported another strong quarter with both earnings and sales beating expectations. Moreover, the company raised the lower end of its earnings outlook for the year.

    The healthcare giant’s third-quarter 2016 earnings came in at $1.68 per share, beating the Zacks Consensus Estimate of $1.65 per share and increasing 12.8% from the year-ago period.

    Sales came in at $17.82 billion, beating the Zacks Consensus Estimate of $17.72 billion. Sales increased 4.2% from the year-ago quarter, reflecting an operational increase of 4.3% and negative currency impact of 0.1%. Strong pharmaceutical sales once again drove the top line.

    Third quarter sales grew 6.7% in the domestic market to $9.38 billion and 1.5% in international markets to $8.44 billion, reflecting 1.7% operational growth, partially offset by 0.2% negative currency impact.

    Including one-time items, Johnson & Johnson reported third quarter earnings of $1.53 per share, up 27.5% from the year-ago period.

    Pharma Segment Delivers Again

    J&J’s pharmaceutical segment once again drove results with new as well as core products performing well. Pharma segment sales grew 9.2% year over year to $8.4 billion, reflecting 9% operational growth and a 0.2% positive currency impact.

    Sales in the domestic market increased 11.8% to $5.04 billion, while international sales grew 5.4% to $3.36 billion.

    New products like Imbruvica, Xarelto and Darzalex continued to perform well. Other growth drivers include Stelara, Invega Sustenna, Remicade and Simponi.

    Hepatitis C virus (HCV) treatment Olysio continued to feel the impact of additional competition with sales declining 73.4% from the year-ago quarter. Invega sales also declined due to generic competition. Invokana/Invokamet sales declined 3.5% in the quarter.

    J&J’s pharma segment also achieved some clinical milestones during the quarter including label expansion for products like Invokamet and Stelara.

    The Medical Devices segment sales came in at $6.2 billion, up 1.1% from the year-ago period, comprising an operational increase of 0.7% and positive currency movement of 0.4%.

    Sales in the domestic market grew 1.4% year over year to $3.05 billion. International market sales inched up 0.7% year over year to $3.11 billion.

    Operational growth was driven by endocutters and energy in the Advanced Surgery business; electrophysiology products in the Cardiovascular business; Acuvue contact lenses in the Vision Care business; and joint reconstruction and trauma products in the Orthopedics business.

    The company is working on driving growth in the Medical Devices segment through new product launches and by transforming its commercial models.

    The Consumer segment recorded revenues of $3.3 billion in the reported quarter, down 1.6% from the third quarter of 2015. Foreign currency movement negatively impacted sales in the segment by 1.7%. Sales in the domestic market grew 1.1% from the year-ago period to $1.3 billion.

    Meanwhile, the international segment recorded a decline of 3.3% to $1.97 billion, reflecting an operational decrease of 0.6% and negative currency impact of 2.7%.

    Products that performed well include Aveeno skin care products and digestive health products; international anti-smoking aids in OTC products; and Listerine oral care products. Lower trade inventory levels, primarily in the U.S., however hurt sales to an extent.

    Earnings Guidance Raised Once More

    Johnson & Johnson raised the lower end of the 2016 earnings guidance. It now expects earnings per share in the range of $6.68 - $6.73 compared with $6.63 - $6.73 expected earlier. We remind investors that J&J had raised its 2016 earnings guidance at the second quarter call as well.

    The revenue guidance was maintained in the range of $71.5 billion - $72.2 billion.

    JOHNSON & JOHNS Price, Consensus and EPS Surprise

    The company carries a Zacks Rank #3 (Hold).

    Our Take

    Johnson & Johnson delivered another strong quarter with both earnings and revenues surpassing expectations. The Pharmaceutical segment continues to perform well despite challenges like generic competition for a few products, negative currency impact and lower HCV revenues. In this regard, we would like to mention that Pfizer Inc. (PFE - Free Report) announced on Monday that its Inflectra injection, a biosimilar version of J&J’s blockbuster drug Remicade, will be available in the U.S. in late November. This should pose strong competition to Remicade.

    The company also raised its earnings outlook for the year. Contribution from new products, share buybacks and the restructuring initiative should help drive results.

    Stocks to Consider

    Some better-ranked stocks in the healthcare sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . Both the stocks have a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

    Exelixis has an average positive surprise of 9.10% over the trailing four quarters. Its share price has jumped 104% year to date. The loss estimates for both 2016 and 2017 have narrowed down over the past 60 days.

    Loss estimates for BioMarin have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.

    Return to headline | Return to top

12. Pfizer to launch biosimilar version of J&J's Remicade in Nov.

    Oct 18, 2016 | Becker's Hospital Review

    By Mackenzie Bean

    New York City-based Pfizer will start shipping its biosimilar copy of Johnson & Johnson's best-selling arthritis drug Remicade in November, offering the drug at a 15 percent discount, according to Reuters.

    The FDA approved Pfizer's biosimilar, known as Inflectra, in April. Once released, it will be the second biosimilar drug available in the U.S., according to the report.

    Pfizer and New Brunswick, N.J.-based J&J are in ongoing litigation regarding whether Inflectra infringes on Remicade's patents.

    In an emailed statement to Reuters, J&J said it considers any Inflectra sales to be an "at risk launch," referring to Pfizer putting the drug on the market before resolving the outstanding patent lawsuit. If the court determines Pfizer infringed on Remicade patents, Inflectra will be taken of the market and J&J will be entitled to triple damages, according to the report.

    Michael Weinstein, an analyst at JP Morgan, estimated J&J will lose about $1 billion in Remicade' revenue for 2017 as a result of Inflectra's upcoming presence in the market.

    Return to headline | Return to top

13. Jefferies Group Comments on Johnson & Johnson’s FY2018 Earnings (JNJ)

    Oct 18, 2016 | Web Breaking News

    By Tony Sherman

    Johnson & Johnson (NYSE:JNJ) – Stock analysts at Jefferies Group lowered their FY2018 earnings estimates for Johnson & Johnson in a report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will earn $7.16 per share for the year, down from their prior forecast of $7.30. Jefferies Group currently has a “Hold” rating and a $115.00 price objective on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.52 EPS.

    A number of other equities research analysts have also issued reports on the company. Vetrraised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 target price on the stock in a research report on Monday, October 3rd. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 28th. Credit Suisse Group AG reaffirmed a “neutral” rating and set a $123.00 target price on shares of Johnson & Johnson in a research report on Monday, September 19th. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $120.20.

    Shares of Johnson & Johnson (NYSE:JNJ) traded down 2.73% during midday trading on Monday, hitting $115.26. The company had a trading volume of 10,449,425 shares. The company’s 50 day moving average is $118.71 and its 200 day moving average is $117.56. The firm has a market cap of $315.34 billion, a price-to-earnings ratio of 21.48 and a beta of 0.62. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07.

    Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, beating the consensus estimate of $1.65 by $0.03. The business had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.49 EPS.

    In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The transaction was disclosed in a legal filing with the SEC, which is available atthis hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

    A number of institutional investors have recently bought and sold shares of JNJ. Avalon Advisors LLC boosted its position in Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock valued at $44,457,000 after buying an additional 101,250 shares during the period. Fisher Asset Management LLC boosted its position in Johnson & Johnson by 0.4% in the first quarter. Fisher Asset Management LLC now owns 10,854,263 shares of the company’s stock valued at $1,195,923,000 after buying an additional 38,299 shares during the period. British Columbia Investment Management Corp boosted its position in Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock valued at $200,052,000 after buying an additional 17,000 shares during the period. Legal & General Group Plc boosted its position in Johnson & Johnson by 1.7% in the first quarter. Legal & General Group Plc now owns 13,449,262 shares of the company’s stock valued at $1,455,269,000 after buying an additional 226,357 shares during the period. Finally, Investec Asset Management LTD boosted its position in Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock valued at $546,454,000 after buying an additional 1,665,644 shares during the period. 65.32% of the stock is owned by hedge funds and other institutional investors.

    About Johnson & Johnson

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

14. Pfizer’s spoiler on Johnson & Johnson’s earnings rally

    Oct 18, 2016 | Proactive Investors

    By George Matlock

    The world’s largest healthcare company Johnson & Johnson’s (NYSE:JNJ) third-quarter earnings per share came in 3 cents higher than analysts’ forecasts.

    J&J came in two cents above estimates with adjusted third quarter profit of $1.68 per share and with revenue beating the street forecast as well. The company raised its full-year forecast, thanks in part to increased drug sales.

    But it wasn’t a good day for the stock, which ended down after rival drugs group Pfizer(NYSE:PFE) announced overnight said it would release a cheaper version of JNJ’s immune drug Remicade – before offering the knock-out blow on Tuesday when it confirmed its Inflectra injection, a biosimilar version of Johnson & Johnson’s JNJ blockbuster drug Remicade, will be available in the US in late November.

    Pfizer also enumerated that its drug would be 15% cheaper than J&J’s current wholesale prices.

    With annual US sales of $5bn and its wide use to also treat Crohn's disease and psoriasis, Remicade is J&J's biggest product. Biosimilar drugs are close copies intended to provide savings compared with costly branded products. Inflectra is already available in Europe.

    But Pfizer is playing for high stakes in the US backyard for both companies. J&J is appealing an August federal court decision that invalidated a US Remicade patent, setting the stage for a February court battle with Pfizer. Should Pfizer launch Inflectra and later lose the court fight, that could entitle J&J to triple damages.

    In the meantime, analysts predicted US Remicade sales will fall 15 to 20% in 2017 - even though J&J on Tuesday predicted the vast majority of patients taking Remicade are unlikely to switch to a biosimilar.

    Of course, should US voters opt to elect drug price crusader Hillary Clinton as the next White House occupant next month, the spat between J&J and Pfizer may be compared with re-arranging the deck chairs on the Titanic ship.

    J&J shares closed down 2.6% at $115.39 while Pfizer was up 0.6% at $32.69 on Tuesday.

    Return to headline | Return to top

15. Johnson & Johnson Brushes Off Looming Biosimilar Competition, Posts Solid Results

    Oct 18, 2016 | Wall Street Journal

    By Jonathan Rockoff and Anne Steele

    Johnson & Johnson on Tuesday sought to reassure investors and analysts that lower-priced competition for one of its top-selling products won’t slow a company that posted slightly better-than-expected results in the third quarter.

    The health-products company said world-wide sales in the quarter grew by 4.2%, to $17.8 billion. The company reported profit of $4.27 billion, or $1.53 a share, up from $3.36 billion, or $1.20 a share, in the same period a year ago.

    Looking ahead, J&J lifted the low end of its financial guidance for the year.

    J&J’s shares have performed strongly, up 15% this year, propelled by a drugs business that has been delivering new big sellers. But shares fell 2% Tuesday morning as investors digested the announcement from rival Pfizer Inc. late Monday that it planned to challenge J&J’s Remicade rheumatoid-arthritis treatment by launching a lower-priced copy, known as a biosimilar, in late November.

    Pfizer said its biosimilar, called Inflectra, would list for a price 15% less than Remicade’s.

    Remicade was J&J’s top-selling drug in the quarter, with $1.2 billion in U.S. sales alone. Chief Financial Officer Dominic Caruso said on a conference call that J&J didn’t expect its yearly results to be affected by any Inflectra competition.

    Analysts say the competition could reduce Remicade sales by $1 billion next year. Yet J&J officials sought to push back on concerns about the impact, especially in the near-term. They noted the company is fighting Inflectra in the courts.

    Joaquin Duato, J&J’s pharmaceuticals chief, also said the company expected stable Remicade patients to stay on the therapy, and that J&J will compete on price. The discount Pfizer is offering on Inflectra is at the bottom of the range that analysts and payers had expected.

    J&J also detailed how new uses for existing medicines and drug launches through 2019 could offset any sales losses and provide new revenue growth.

    Mr. Duato said the company is working on 10 line extensions on existing products that could add more than $500 million in sales apiece and 10 new drugs that could have $1 billion or more in sales each.

    “We plan to continue to grow our pharmaceuticals business in the face of biosimilar competition,” including in the treatment of immunology diseases like the ones treated by Remicade, Mr. Duato said in an interview.

    The New Brunswick, N.J., company now expects earnings for the year of $6.68 to $6.73 a share, compared with its previous guidance for $6.63 at the bottom end of the range. It repeated its revenue forecast of $71.5 billion to $72.2 billion.

    Prescription-drug sales grew 9.2% to $8.4 billion in the quarter, driven by strength in new products including blood-cancer drug Imbruvica, blood-thinner Xarelto and multiple myeloma therapy Darzalex.

    J&J’s other segments, however, continued to lag. During the quarter, sales of J&J consumer health products slipped 1.6% to $3.26 billion, dragged down by currency headwinds. Meanwhile, J&J’s medical device sales rose just 1.1% to $6.16 billion.

    Return to headline | Return to top

16. (UPDATE) Johnson & Johnson Again Buoyed by Pharmaceuticals

    Oct 18, 2016 | Wall Street Journal

    By Anne Steele

    Johnson & Johnson lifted the low end of its guidance and posted better-than-anticipated results in the latest quarter as the health-care giant’s pharmaceutical business continues to buoy its top line.
    

    The New Brunswick, N.J., company now expects earnings for the year of $6.68 to $6.73 a share, compared with its previous guidance for $6.63 on the bottom. It backed its revenue forecast of $71.5 billion to $72.2 billion.
    

    Chief Executive Alex Gorsky said results reflect the success of new product launches and the strength of core businesses, “driven by strong growth in our pharmaceuticals business.”
    

    “With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” he said.
    

    Still, J&J faces the threat of lower-priced competition emerging for some top-selling prescription drugs. And with about half of its sales overseas, J&J’s results have been pressured by a strengthening U.S. dollar and weakness in some emerging markets.
    

    On Monday, Pfizer Inc. said it would begin selling a biosimilar version of blockbuster rheumatoid-arthritis treatment Remicade in late November at a 15% discount to the brand-name drug’s list price. J&J promised to fight the biosimilar’s launch, setting up for a fierce battle between two of the biggest drug companies in the world in the courts as well as in contract talks with health insurers.
    

    During the most recent period, sales of Remicade—one of J&J’s top sellers—surged 18% world-wide, as the pharmaceutical business, the company’s largest, continued to propel J&J. Prescription-drug sales grew 9.2% to $8.4 billion, driven by strength in new products including blood-cancer drug Imbruvica, blood thinner Xarelto and multiple myeloma drug Darzalex. Worldwide remicade
    

    J&J’s other segments, however, continued to lag. During the quarter, sales of J&J consumer health products slipped 1.6% to $3.26 billion, dragged down by currency headwinds.
    

    Meanwhile, J&J’s medical device sales rose just 1.1% to $6.16 billion. The business used to be J&J’s largest, but has stumbled amid pricing pressures, increased competition and market changes. In response, J&J has exited certain areas, rejiggered how it sells devices and focused on high-growth categories like robotics and staplers.
    

    In all for the September quarter, J&J posted a profit of $4.27 billion, or $1.53 a share, up from $3.36 billion, or $1.20 a share, in the same period a year ago.
    

    Excluding certain items, adjusted earnings ticked up to $1.68 a share. Analysts polled by Thomson Reuters were looking for an adjusted $1.66 a share. Revenue climbed 4.2% to $17.8 billion, edging in just above analyst estimates for $17.74 billion. Unfavorable currency rates shaved 0.1% off the quarter’s total.
    

    Shares, which have risen 15% so far this year, lost 0.4% premarket to $118.03.

    Return to headline | Return to top

17. (UPDATE – 3) Johnson & Johnson tops 3Q Street view but shares decline

    Oct 18, 2016 | Associated Press

    By Linda A. Johnson

    Johnson & Johnson shares dropped Tuesday, despite the health care bellwether boosting its third-quarter profit 27 percent. Investors apparently are worried about unexpectedly early competition to the company's longtime top seller.
    

    The maker of Band-Aids, medical devices and prescription drugs beat Wall Street's expectations, maintained its 2016 revenue forecast, raised the lower end of its profit forecast and said it's on track for the approval and launch of 10 new medicines between 2015 and 2020.
    

    But on a conference call after the results were released, analysts peppered J&J executives with questions about how it will prevent Pfizer Inc.'s Inflectra from siphoning off sales of J&J's biologic immune disorder drug Remicade, which has earned J&J tens of billions of dollars since its 1998 launch.
    

    On the eve of J&J's results announcement, Pfizer said Monday it will launch a near-copy of the injected biologic drug, called a biosimilar, in late November in the U.S.
    

    Many analysts didn't expect that competition until 2018 because Pfizer and J&J are still fighting in the courts over whether the U.S. patent protecting Remicade's monopoly is still valid, said Edward Jones analyst Ashtyn Evans. If Pfizer loses that litigation, it could have to pay J&J three times the U.S. profits it makes on Inflectra, she noted.
    

    Investors are "beginning to price in the competition" to Remicade, driving down J&J's price, Evans said.
    

    In midday trading, J&J shares fell $2.36, or 2 percent, to $116.13, as the broader markets rose.
    

    Remicade, for treating rheumatoid arthritis, psoriasis, Crohn's disease and colitis, is one of J&J's most profitable drugs, with sales of $5.34 billion in the first three quarters.
    

    Inflectra will be priced 15 percent less than Remicade's roughly $2,600 monthly list price and is sure to cut into Remicade sales, as biosimlars have already done in Europe and Canada.
    

    J&J executives told the analysts that about 70 percent of patients taking Remicade are doing well and unlikely to change drugs, the company has a strong patient assistance program and it's offering sizeable discounts to insurers.
    

    "I think on top of market share loss you're going to see lower prices" offered on Remicade as many new patients opt for Inflectra due to the lower price, Evans predicted.
    

    The world's biggest maker of health care products on Tuesday reported net income of $4.27 billion, or $1.53 per share, up from $3.36 billion, or $1.20 per share, in 2015's third quarter. Restrained spending and soaring prescription drug sales more than offset a dip in consumer product sales.
    

    Adjusted earnings, which exclude one-time items, amounted to $1.68 per share, 3 cents better than analysts expected.
    

    The New Brunswick, New Jersey-based company posted revenue of $17.82 billion in the quarter, up from $17.1 billion a year ago and above the $17.72 billion analysts expected.
    

    Sales of prescription drugs, J&J's largest business, jumped 9.2 percent to $8.4 billion, led by $1.8 billion for Remicade. Xarelto, for preventing strokes and heart attacks, saw sales jump 15 percent to $529 million in the quarter, while sales of biologic psoriasis drug Stelara soared 33 percent to $814 million and sales of new leukemia and lymphoma treatment Imbruvica nearly doubled to $349 million.
    

    Medical device sales edged up 1.1 percent to $6.16 billion, while sales of consumer health products such as Tylenol and Motrin pain relievers fell 1.6 percent to $3.26 billion.
    

    Johnson & Johnson said it expects full-year adjusted earnings in the range of $6.68 to $6.73 per share, up from its July forecast of $6.63 to $6.73 per share. It affirmed its earlier forecast for revenue of $71.5 billion to $72.2 billion.

    Return to headline | Return to top

18. J&J says pharma future bright, despite threat to Remicade

    Oct 18, 2016 | Reuters

    By Ransdell Pierson

    Booming pharmaceutical sales drove strong quarterly results for Johnson & Johnson (JNJ.N), but the company's shares fell more than 2 percent on worries that its blockbuster Remicade arthritis drug would soon face cheaper competition.

    Pfizer Inc (PFE.N) late on Monday said it would begin U.S. shipments of Inflectra, its biosimilar form of Remicade, by late November at a 15 percent discount to J&J's current wholesale prices.
    

    With annual U.S. sales of about $5 billion and its wide use to also treat Crohn's disease and psoriasis, Remicade is J&J's biggest product. Biosimilar drugs are close copies intended to provide savings compared with costly branded products. Inflectra is already available in Europe.

    J&J is appealing an August federal court decision that invalidated a U.S. Remicade patent, setting the stage for a February court battle with Pfizer. Should Pfizer launch Inflectra and later lose the court fight, that could entitle J&J to triple damages. In the meantime, analysts predicted U.S. Remicade sales will fall 15 to 20 percent next year, even though J&J on Tuesday predicted the vast majority of patients taking Remicade are unlikely to switch to a biosimilar. "There's fear what happens to Remicade," said Guggenheim Securities analyst Tony Butler. "It will lose some market share." But Edward Jones analyst Ashtyn Evans predicted J&J's annual pharmaceutical sales will grow in the "high single digit" percentage range over the next 3 to 5 years, despite Remicade's decline, as newer drugs for inflammatory conditions and cancer continue post strong sales.
    

    J&J shares fell 2.6 percent to $115.43 in afternoon trade. In the third quarter, J&J revenue rose to $17.82 billion from $17.10 billion a year earlier. Its pharmaceutical sales jumped 9.2 percent to $8.40 billion, with strong growth for its new Imbruvica and Darzalex cancer drugs and its blood thinner Xarelto. U.S. sales of Remicade jumped 9.4 percent to $1.22 billion. Global medical device sales rose 1.1 percent to $6.16 billion in the quarter, while consumer product sales fell 1.6 percent to $3.26 billion. J&J raised the lower end of its full-year 2016 profit forecast to $6.68 per share from $6.63 a share. It retained the upper end at $6.73 per share. The company's net earnings rose to $4.27 billion, or $1.53 per share, in the third quarter, from $3.36 billion, or $1.20 per share, a year earlier. Excluding special items, J&J earned $1.68 per share, topping the average analyst forecast of $1.66 per share, according to Thomson Reuters I/B/E/S.

    Return to headline | Return to top

19. Pfizer's Remicade Rudeness Shouldn't Faze J&J

    Oct 18, 2016 | Bloomberg

    By Max Nisen

    The pharma world can be cutthroat as firms jockey for position with competing drugs. But even in that context, Pfizer's decision to announce a late-November launch of its competing version of Johnson & Johnson's best-selling drug Remicade the afternoon before J&J released its third-quarter earnings seems a bit cold. 

    Pfizer's announcement cast a shadow on another blockbuster quarter from J&J, whose shares fell 2.7 percent on Tuesday. But J&J isn't going to let Remicade's $6.5 billion in sales slip gently into the good night. And it's better positioned than just about any other company to weather such a storm. Down, Not OutConcerns about competition for its best selling drug Remicade dropped Johnson & Johnson shares Tuesday.Source: BloombergIntraday times are displayed in ET.

    Pfizer's drug, Inflectra, is not your standard generic. J&J's drug Remicade is what's known as a biologic drug, made with living cells instead of a chemical process. It's impossible to copy exactly; hence the term "biosimilar." The regulatory tango involved in getting such a drug approved is about as complicated as making it. 

    Inflectra is just the second biosimilar to hit the U.S. market. It's going to be a huge test of how willing doctors are to prescribe biosimilars, how aggressive payers will be in pushing them, and how firms will fight for biologic market share over the next decade. 

    Remicade sales helped Johnson & Johnson top earnings estimates in the latest quarter. Sales of the drug grew more than 10 percent from a year ago -- but such performance likely won't be seen again.

    Merck markets the drug in Europe and splits the profits with Johnson & Johnson. Biosimilars first launched in that region in February of last year, and Merck saw sales drop by more than $500 million compared to 2014, a substantially bigger decline than what analysts currently expect for J&J in 2017. Patent Bunny Slope?Analysts expect a relatively slow dropoff in J&J's Remicade sales as biosimilar copies hit the U.S. market.

    Things are a bit more complicated in the U.S.

    Pfizer's drug is an "at risk" launch; there are still outstanding patent appeals that could tangle things up. The FDA has yet to release guidance that would make it easier for pharmacists to switch patients from Remicade to Inflectra. Pfizer is also pricing its drug at a relatively modest 15 percent discount, which may help J&J minimize the sales impact. 

    The J&J company line, per its earnings call, is that it already faces biosimilar competition elsewhere and has managed to preserve most of its market share. It argues doctors and patients will be reluctant to switch and expects only a "modest" impact from Pfizer's launch.  

    Remicade sales will drop -- possibly more than expected, if it loses major market share or payers press J&J for discounts. 

    That means J&J must rely on its pipeline for future growth -- but there are worse things. Last year, J&J committed to file for regulatory approval for a total of 10 drugs with at least $1 billion peak sales potential each by 2019. One of those, the cancer drug Darzalex, has already been approved.

    By 2019, the company also expects to file for 10 line extensions -- expanded approvals for existing drugs -- that it says could account for at least $500 million each in peak sales. If even a modest portion of that forecast is met, then Remicade becomes much less of a worry.

    Though J&J's device and consumer businesses are declining in relative importance, they still combined to deliver $9.4 billion in sales in the quarter and give the company a steady base other competing pharma firms lack. That makes J&J less dependent on Remicade.

    Yes, the drug accounted for 21 percent of pharmaceutical sales in the latest quarter. But it provided only 10 percent of J&J's total sales. Contrast that with AbbVie, whose biosimilar-threatened blockbuster Humira accounted for 64 percent of revenue in the second quarter. 

    If that's not enough, J&J also has $42.5 billion in cash on hand and is on the hunt for pharma acquisitions. It's on its way to more than $72 billion in revenue in 2016 and delivers on or exceeds expectations quarter after quarter.

    Always On TimeJohnson & Johnson has made a habit of beating or exceeding analyst's quarterly earnings expectations.

    Adjusted to make comparable with Bloomberg estimates

    If Pfizer wants to truly rattle J&J, it may have to try a bit harder. 

    Return to headline | Return to top

20. (UPDATE – 2) J&J Falls as Cheaper Competition for Blockbuster Remicade Looms

    Oct 18, 2016 | Bloomberg

    By Jared S Hopkins

    Johnson & Johnson’s shares fell on concerns about the looming introduction of cheaper versions of the drugmaker’s blockbuster arthritis treatment Remicade.
    

    The shares dropped as much as 2.7 percent on Tuesday, the biggest decline in more than eight months, as Remicade’s outlook overshadowed better-than-expected results for the third quarter and a raised profit forecast for 2016.
    

    Revenue from top-selling Remicade jumped 11 percent to $1.78 billion last quarter, accounting for 21 percent of J&J’s pharmaceuticals sales and topping the $1.68 billion average of analysts’ predictions. But the treatment will soon face cheaper copies known as biosimilars, starting with one from Pfizer Inc. next month. Pfizer announced its biosimilar, Inflectra, Monday after the close, saying it will cost 15 percent less than Remicade.
    

    “This is all about the future,” said Tony Butler, an analyst at Guggenheim Securities LLC, who rates the stock as neutral. “The one thing that can possibly create some angst is the biosimilar entry against Remicade."
    

    The shares were down 2.3 percent to $115.81 at 11:29 a.m. in New York. Through Monday, they had fallen 5.5 percent from their all-time high of $125.40 on Aug. 1, mirroring an industrywide slide as political scrutiny over U.S. drug prices has intensified.
    

    J&J plans to defend the remaining Remicade patents that don’t expire until 2018, Chief Financial Officer Dominic Caruso said on Bloomberg TV. The company is prepared to battle against the biosimilar, which is expected to have a “modest” impact on sales, he said on conference call with analysts. Remicade is already competitively priced against other treatments, he said.
    

    “So, the amount of discounting and competitive atmosphere we’re very well accustomed to, and we are competing very well there,” he said on television. 
    

    Third-quarter earnings excluding some items were $1.68 a share, the company said Tuesday in a statement. That compared with the $1.65 average of 19 predictions compiled by Bloomberg.
    

    Pharmaceuticals overtook medical equipment as J&J’s biggest unit two years ago, and the New Brunswick, New Jersey-based company is counting on its drug pipeline to offset the impact from biosimilars on Remicade. They include blood cancer treatment Imbruvica, which beat estimates last quarter. Other products, like diabetes medicine Invokana and blood thinner Xarelto, came in lower than anticipated.
    

    The drugmaker narrowed its 2016 earnings-per-share guidance to $6.68 to $6.73 from a previous range of $6.63 to $6.73. Analysts anticipated $6.70. The company maintained its revenue guidance of $71.5 billion to $72.2 billion.
    

    As pharmaceuticals continue to be the strongest unit, the division’s five therapeutic areas represent “logical” target areas for potential acquisitions, Caruso said. They are infectious, immunology, neuroscience, oncology and cardiovascular. Medical-devices sales, which rose by 1.1 percent to $6.16 billion, show that the division is “coming back,” the CFO also said. Potential areas for expansion include cardiovascular products.
    

    “We are wide open to do good transactions at the right price at the right time,” Caruso said.
    

    Here are the highlights for the third-quarter:
    Sales were in line at $17.8 billion. Analysts anticipated $17.7 billion. Net income rose 27 percent percent to $4.27 billion, or $1.53 a share, from $3.36 billion, or $1.20 a share Stelara $814 million versus estimate of $764 million Zytiga $582 million versus estimate of $559 million Xarelto $529 million versus estimate of $564 million Simponi $481 million versus estimate of $428 million Invokana $328 million versus estimate of $404 million

    Return to headline | Return to top

21. Johnson & Johnson beat profit and sales expectations, lifts earnings outlook

    Oct 18, 2016 | Market Watch

    By Tomi Kilgore

    Johnson & Johnson JNJ, +0.26% reported Tuesday third-quarter earnings that rose to $4.27 billion, or $1.53 a share, from $3.36 billion, or $1.20 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.68, beating the FactSet consensus of $1.65. Revenue increased 4.2% to $17.82 billion, above the FactSet consensus of $17.74 billion, as bigger-than-expected increases in pharmaceutical and medical devices sales offset less-than-expected consumer sales. Looking ahead, the drug and consumer products giant lifted its EPS outlook to $6.68 to $6.73 from $6.63 to $6.73, and kept its revenue outlook at $71.5 billion to $72.2 billion. "With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Chief Executive Alex Gorsky. The stock, which was indicated about 1% higher in premarket trade, has climbed 15% year to date through Monday, while the Dow Jones Industrial Average DJIA, -0.29% has gained 3.8%.

    Return to headline | Return to top

22. Johnson & Johnson (JNJ) Releases Earnings Results, Beats Expectations By $0.02 EPS

    Oct 18, 2016 | Market Digest

    By Aaron Hall

    Johnson & Johnson (JNJ) announced its most recent quarterly financial results on Tuesday, Oct-18-2016. JNJ said it had a profit of $1.68 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $1.66. The company posted revenue of $17820.00 million in the period, compared to analysts expectations of $17744.90 million. JNJ’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS.

    Johnson & Johnson closed down -0.7 points or -0.59% at $117.56 with 56,40,519 shares getting traded on Friday. Post opening the session at $118.5, the shares hit an intraday low of $117.56 and an intraday high of $118.8 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

    In a different news, on Jul 28, 2016, Dominic J Caruso (Exec VP, Finance; CFO) sold 41,146 shares at $125.01 per share price. According to the SEC, on Jul 25, 2016, Ronald A Kapusta (Controller, CAO) sold 2,935 shares at $125.01 per share price. On Jun 9, 2016, Gary J Pruden (Exec VP, WW Chair, Med Devices) sold 9,735 shares at $116.03 per share price, according to the Form-4 filing with the securities and exchange commission.

    Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

    Return to headline | Return to top

23. (UPDATE–2) J&J revenue, profit edge past estimates on robust drug sales

    Oct 18, 2016 | Reuters

    By Natalie Grover

    Johnson & Johnson (JNJ.N), the world's largest maker of healthcare products, reported third-quarter revenue and profit just ahead of Wall Street estimates, fueled by strong sales in its prescription drugs business.

    J&J, the first major U.S. drugmaker to report quarterly results, said pharmaceutical drug sales jumped 9.2 percent to $8.40 billion, buoyed by demand for its cancer medicines, Imbruvica and Darzalex, as well as its blood thinner Xarelto.

    The company is increasingly confident of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion, Chief Executive Alex Gorsky said in a statement on Tuesday.

    Sales of the company's autoimmune drug Remicade - its biggest product - rose 10.5 percent to $1.78 billion in the quarter.

    However, the company is set to face competition for Remicade in the United States.

    Pfizer Inc (PFE.N) said on Monday it would begin shipping its biosimilar version of Remicade in late November at a 15 percent discount to current wholesale prices.

    The Pfizer drug, Inflectra, is already available in Europe and other overseas markets, and was approved by U.S. health regulator earlier this year, but a protracted patent battle impacted its launch.

    J&J said in July its forecast for Remicade had assumed no competition from a biosimilar in the United States this year.

    The maker of a variety of products from Tylenol to Band-Aid bandages to Acuvue contact lenses raised the lower end of its adjusted profit range to $6.68 per share from $6.63 on Tuesday.

    The company retained the upper end at $6.73 per share, and also backed its revenue forecast for the year.

    Global device sales inched up 1.1 percent to $6.16 billion in the third quarter, while consumer product sales fell about 1.6 percent to $3.26 billion.

    The New Jersey-based company is restructuring its medical device business to focus on areas such as artificial knees and devices for trauma surgery.

    J&J agreed last month to buy Abbott Laboratories' (ABT.N) medical optics business for $4.3 billion.

    Excluding special items, J&J earned $1.68 per share on revenue of $17.82 billion.

    Analysts on average had expected a profit of $1.66 per share and revenue of $17.74 billion, according to Thomson Reuters I/B/E/S.

    Up to Monday's close, J&J's shares had gained about 15 percent since the start of the year, compared with the 3.7 percent decline in the S&P 500 healthcare sector .SPXHC.

    Return to headline | Return to top

24. J&J prepares for drug price war with Pfizer

    Oct 18, 2016 | Financial Times

    By David Crow

    Johnson & Johnson set the stage for a price war in one of the most lucrative segments of the pharmaceuticals industry, as it announced its intention to discount its top-selling arthritis drug following the introduction of a cheaper knock-off version.

    “We’re ready to compete in every channel, trying to bring patients the most affordable option in every situation,” Joaquin Duato, J&J’s worldwide chairman of pharmaceuticals, said on Tuesday, a day after Pfizer announced it would start selling a copycat of Remicade from next month. 
    

    Remicade, an anti-inflammatory drug for conditions including rheumatoid arthritis, is J&J’s best-selling medicine by far, generating $5.3bn of sales in the first nine months of this year.

    The medicine already faces overseas competition from so-called biosimilars but Pfizer is the first drugmaker to launch a version in the US market, which accounts for more than two-thirds of sales.

    The introduction of biosimilars poses a threat to the pharmaceuticals industry, which has struggled for decades to weather the loss of patent protection on top-selling drugs.

    Many of today’s most successful medicines are derived from living cells, meaning they cannot be copied as easily as a simple pill — but regulators have become increasingly comfortable with biosimilar versions that are almost the same as the original product.

    Pfizer’s drug Inflectra will go on sale with a list price of $946.28 a vial, a 15 per cent discount to Remicade. But the negotiated price for either drug is certain to be much lower as both companies offer big discounts to health insurers and pharmacy benefit managers to bolster their market share.

    Shares in J&J fell 1.7 per cent in early New York trading.

    Mr Duato said 70 per cent of patients had found stability with Remicade and were “highly unlikely to switch” to Inflectra, adding that the company would protect its turf with “innovative contracting” and by offering financial assistance to patients who find the medicine too expensive.

    He said the company had retained a market share of more than 90 per cent in some countries where a biosimilar has been launched, such as Brazil, Canada and Australia.

    J&J said it would also continue to fight the introduction of Inflectra in the courts, on the grounds that Pfizer is infringing its patents.

    Meanwhile, J&J predicted that a string of its experimental medicines would become “blockbuster” drugs by 2019 with annual revenues in excess of $1bn, potentially offsetting lower revenues from Remicade.

    It identified five drugs that it said offered “significant near-term opportunities”, especially Darzalex, a medicine that has been shown to dramatically increase the chances of those suffering from multiple myeloma, a bone marrow cancer.

    “Since 2015, our expectations around these near-term opportunities have crystallised. Our latest information provides higher certainty that these products will succeed, delivering higher value than originally anticipated,” said Mr Duato.

    J&J posted adjusted earnings of $1.68 per share for the third quarter, about 3 cents ahead of Wall Street expectations. Revenues were $17.8bn, roughly $60m higher than the typical analyst forecast.

    Return to headline | Return to top

25. Johnson & Johnson Delivers Another Earnings Beat

    Oct 18, 2016 | Benzinga

    By R. Chandrasekaran

    Johnson & Johnson JNJ delivered better than expected results for the third quarter, as earnings and revenue came in above the Street estimates.

    The company earned a profit of $4.3 billion, or $1.53, up from $3.36 billion, or $1.20 a share, in the year-ago quarter. On an adjusted basis, it would have earned $4.7 billion or $1.68 a share representing a year-over-year growth of 12.2 and 12.8 percent respectively. Analysts estimated the company to earn $1.65 a share.

    Johnson & Johnson net sales grew 4.2 percent to $17.8 billion and came in above the Street predictions of $17.74 billion. While domestic sales advanced 6.7 percent, global sales grew 1.5 percent to reflect an operational growth of 1.7 percent with currency's 0.2 percent unfavorable impact.

    Chairman and CEO Alex Gorsky commented, "With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion."

    Moving ahead, the healthcare products producer reiterated its sales outlook of $71.5-$72.2 billion and adjusted EPS forecast of $6.68-$6.73 for the full year. Street is looking for an EPS of $6.69 on revenue of $72.16 billion.

    The stock traded up by $1.10, or 0.93 percent, to $119.59 in pre-market trading.

    Return to headline | Return to top

26. Johnson & Johnson Q3 Profit Tops Estimates; Raises FY16 Adj. EPS Guidance

    Oct 18, 2016 | RTT News

    Johnson & Johnson (JNJ) reported third-quarter net earnings of $4.3 billion or $1.53 per share compared to $3.4 billion or $1.20 per share, prior year. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted earnings per share also increased 12.8%. On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $1.65 for the quarter. Analysts' estimates typically exclude special items.

    Third-quarter sales were $17.82 billion, an increase of 4.2% compared to the third quarter of 2015. Operational sales results increased 4.3% and the negative impact of currency was 0.1%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.9%. Analysts expected revenue of $17.74 billion for the quarter.

    "Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticalsbusiness. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion," said Alex Gorsky, CEO.

    Johnson & Johnson maintained its sales guidance for the full-year 2016 of $71.5 billion to $72.2 billion. The company increased its adjusted earnings guidance for full-year 2016 to $6.68 - $6.73 per share. Analysts polled by Thomson Reuters expect the company to report profit per share of $6.69 on revenue of $72.16 billion.

    Return to headline | Return to top

27. Johnson & Johnson Boosts Outlook as Q3 Earnings Beat Estimates

    Oct 18, 2016 | ETF Daily News

    The New Brunswick, NJ-based company reported adjusted Q3 EPS of $1.68, beating out Wall Street’s expectations of $1.66. Revenue rose 4.2% from last year to $17.82 billion, also eclipsing analysts’ view of $17.74 billion.

    Looking ahead, JNJ lifted its full-year earnings forecast. The company now expects 2016 EPS of $6.68-6.73, up from a prior outlook of $6.63-6.73. Analysts are currently looking for $6.69 per share for the year. Johnson & Johnson expects full-year revenue to range from $71.5-72.2 billion, versus analysts’ view of $72.14 billion.

    Other interesting notes from the report included:

    Operational sales rose 4.3%, with Domestic sales gaining 6.7% and International sales rising 1.5%. Worldwide Pharmaceutical sales gained 9.2% to $8.4 billion. Worldwide Consumer sales fell 1.6% to $3.3 billion, hurt by currency effects. When excluding forex, consumer sales would have risen 0.1%. Worldwide Medical Devices sales rose 1.1% to $6.2 billion.

    From the press release:
    

    “Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care.”

    JNJ shares rose $1.10 (+0.93%) to $119.59 in premarket trading Tuesday. Prior to today’s report, JNJ stock had gained 15.35%, easily eclipsing the 4.16% return of the benchmark S&P 500 during the same period.

    Return to headline | Return to top

28. Trader’s Spotlight- Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | Hot Stocks Point

    By Robert Ebelling

    Johnson & Johnson’s (JNJ)’s Stock Price Trading Update:

    Johnson & Johnson’s (JNJ) stock price ended its day with a gain of 0.79% and finalized at the value of $118.49. During its last trading session, Stock traded with the total exchanged volume of 6.94 million shares. The average volume stands around 6.06 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 1.15. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Johnson & Johnson’s (JNJ) is a part of Healthcare sector and belongs to Drug Manufacturers – Major industry.

    Important Technical Indicators:

    ATR value of company was 1.30 and Relative Strength Index (RSI) was 49.04. The stock volatility for week was 1.31% while for month was 1.02%.The stock, as of last close, traded 28.50% to its 52 week low and was changed -5.39% from its 52 week high. Beta factor, which measures the riskiness of the security, was observed as 0.75. JNJ’s value Change from Open was at 0.84% with a Gap of -0.05%.

    Earnings per share Details about JNJ:

    EPS in next five year years is expected to touch 6.53% while EPS growth in past 5 year was 2.80% along with sales growth of 2.60% in the last five years.

    EPS growth in next year is estimated to reach 6.26% while EPS growth estimate for this year is set at -3.90%.

    The price/earnings ratio (P/E) is 22.07 and the forward P/E ratio stands at 16.66. The price to earnings growth is 3.38 and the price to sales ratio is 17. It has a dividend yield of 2.70%.

    Performance Review:

    To review the JNJ previous performance, look at its past history, which highlighted below:

    During last 5 trades the stock sticks almost -1.09%.

    During last one month it showed the change of 0.20%.

    During last 3 month it remained at -4.77%.

    Along with these its year to date performance is standing at 17.80%.

    Analysts Mean Rating:

    Analysts’ mean recommendation for Johnson & Johnson’s (JNJ) stands at 2.50. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

    JNJ Stock Price Comparison to Moving Averages:

    USA based company, Johnson & Johnson’s (JNJ)’s latest closing price was 5.67% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -0.75% and -0.03% compared with the 20 Day Moving Average.

    Return to headline | Return to top

29. Johnson & Johnson Q3 numbers top expectations

    Oct 18, 2016 | Digital Look

    By Michele Maatouk

    Johnson & Johnson posted better-than-expected third-quarter numbers on Tuesday and lifted its earnings outlook for the year.
    

    The company said net earnings for the quarter came in at $4.3bn, or $1.53 a share, up from $3.4bn or $1.20 a share in the same period a year ago. Adjusted EPS rose to $1.68 from $1.49, beating analysts’ expectations of $1.65.
    

    Meanwhile, sales were up 4.2% to $17.8bn, beating expectations of $17.7bn.
    

    The company maintained its sales guidance for the full year 2016 of $71.5bn to $72.2bn but upped its adjusted earnings guidance to $6.68-$6.73 per share. The lower end of the range was previously $6.63.
    

    J&J said worldwide pharmaceutical sales rose 9.2% to $8.4bn, while worldwide medical devices sales edged up 1.1% to $6.2bn. This helped to offset a 1.6% drop in consumer sales to $3.3bn.
    

    Chairman and chief executive officer Alex Gorsky said: “Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1bn.
    

    "Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care."
    

    At 1220 BST, J&J shares were up 0.3% to $118.80 in pre-market trade.

    Return to headline | Return to top

30. J&J raises 2016 profit outlook

    Oct 18, 2016 | USA Today

    By Nathan Borney

    Health products conglomerate Johnson & Johnsonraised its 2016 profit forecast after beating third-quarter expectations for profit and sales.

    J&J added to its reputation for sterling finances with a 4.2% increase in revenue to $17.8 billion and a 27.2% increase in net earnings to $4.3 billion.

    On a per share basis, earnings were $1.53, edgingS&P Global Market Intelligence expectations of $1.51.

    Bolstered by strong performances for products such as Listerine mouth wash and Aveeno skin care, J&J raised its full-year adjusted earnings per share projection to a range of $6.68 per share to $6.73.

    The performance reflected J&J's status as one of only two American companies left with a pristine AAA credit rating. The other, Microsoft, is in danger of losing its mark.

    "Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our pharmaceuticals business," J&J CEO Alex Gorsky said in a statement. "Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care."

    Still, there were a few blemishes on the earnings statement. Excluding the effect of acquisitions and asset divestitures, global sales on an operational basis fell 0.4%.

    And in the consumer products segment, total sales declined 1.6% to $3.3 billion. But that was offset by a 9.2% increase in pharmaceutical sales to $8.4 billion and a 1.1% increase in medical devices revenue to $6.2 billion.

    J&J shares (JNJ) slipped 0.2% to $118.30 in pre-market trading.

    Return to headline | Return to top

31. Johnson & Johnson Earnings Top Estimates on Solid Pharmaceutical Sales

    Oct 18, 2016 | The Street

    By Martin Baccardax

    Johnson & Johnson (JNJ) beat analysts' expectations with its third-quarter earnings Tuesday as pharmaceutical sales notched a solid advance, offsetting weakness in its consumer products group.

    The maker of Band-Aid and Tylenol said adjusted third-quarter earnings per share came in at $1.68, just ahead of the consensus forecast of $1.66. Sales for the three months ended in September were reported at $17.8 billion, the company said, largely in line with the $17.7 billion consensus.

    J&J reiterated its full-year sales guidance of between $71.5 billion and $72.2 billion and said it sees full-year adjusted per share earnings of between $6.68 and $6.73.

    "Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our pharmaceuticals business," CEO Alex Gorsky said in a statement. "With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion."

    J&J's revenue breakdown showed a 9.2% year-on-year rise in worldwide pharmaceutical sales, which hit $8.4 billion, partly offsetting a 1.6% decrease in consumer sales, which slipped to $3.3 billion from the same quarter in 2015. Global medical device sales, the company said, rose 1.1% to $6.2 billion.

    Johnson & Johnson shares closed at $118.49 in New York Monday, and have risen around 15.35% so far this year, well ahead of the 4% decline for the broader S&P health care sector. 

    Return to headline | Return to top

32. Johnson & Johnson’s Q3 numbers top estimates, medical devices biz grows slightly

    Oct 18, 2016 | Mass Device

    By Brad Perriello

    Third-quarter sales ticked up 4% and profits grew at a double-digit clip forJohnson & Johnson (NYSE:JNJ), the company said today, and its medical devices business posted sales growth of just more than 1%.

    The New Brunswick, N.J.-based healthcare giant said its medtech business – the world’s 2nd-largest after Medtronic (NYSE:MDT) – posted sales of $6.16 billion for the 3 months ended Sept. 30. Domestic medical device sales grew 1.4% to $3.05 billion, with international medtech sales at $3.11 billion, up 0.7%.

    Overall profits grew 27.2% to $4.27 billion, or $1.53 per share, on sales of $17.82 billion, for 4.2% top-line growth compared with Q3 2015. Adjusted to exclude 1-time items, profits were up 12.2% to $4.68 billion, or $1.68 per share, 3¢ ahead of expectations on Wall Street. Analysts there were looking for adjusted EPS of $1.65 on sales of $17.74 billion.

    “Our 3rd-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” chairman & CEO Alex Gorsky said in prepared remarks. “Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care.”

    Johnson & Johnson raised its full-year earnings outlook, saying it expects to post adjusted EPS of $6.68 to $6.73, but stood pat on its forecast for sales of $71.5 billion to $72.2 billion.

    JNJ shares closed up 0.8% at $118.49 apiece yesterday, before dipping -0.05% to $117.96.

    Return to headline | Return to top

33. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

    Oct 18, 2016 | Financial Market News

    By Don March

    Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion.

    Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. The firm has a market capitalization of $324.17 billion, a price-to-earnings ratio of 22.08 and a beta of 0.62. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The company’s 50-day moving average is $118.71 and its 200 day moving average is $117.56.

    In other news, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.

    Several institutional investors have recently added to or reduced their stakes in JNJ. Cambridge Trust Co. increased its position in Johnson & Johnson by 3.1% in the second quarter. Cambridge Trust Co. now owns 306,988 shares of the company’s stock worth $37,238,000 after buying an additional 9,161 shares during the last quarter. Hyman Charles D increased its position in shares of Johnson & Johnson by 1.1% in the second quarter. Hyman Charles D now owns 262,363 shares of the company’s stock valued at $31,825,000 after buying an additional 2,748 shares in the last quarter. Argent Trust Co increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Argent Trust Co now owns 39,093 shares of the company’s stock valued at $4,743,000 after buying an additional 238 shares in the last quarter. Dana Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 17.2% in the second quarter. Dana Investment Advisors Inc. now owns 338,166 shares of the company’s stock valued at $41,020,000 after buying an additional 49,573 shares in the last quarter. Finally, Reilly Herbert Faulkner III purchased a new position in shares of Johnson & Johnson during the second quarter valued at about $4,389,000. 65.32% of the stock is owned by institutional investors.

    A number of equities analysts have commented on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective on the stock in a report on Monday, August 22nd. Leerink Swann reiterated an “outperform” rating and issued a $140.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, September 20th. RBC Capital Markets reiterated an “outperform” rating and issued a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Finally, Jefferies Group boosted their price objective on shares of Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a report on Thursday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $120.20.

    Johnson & Johnson Company Profile

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

34. Without Drugs, Johnson & Johnson Has Nothing (JNJ)

    Oct 18, 2016 | Investor Place

    By Dana Blankenhorn

    Johnson & Johnson (NYSE:JNJ) shareholders are waking up with a shrug today. JNJ stock is slightly off after the thinnest of earnings beats, with the save coming from the company’s pharmaceutical business.

    For the quarter ended in September, JNJ earned $4.68 billion, or $1.68 per share, on revenues of $17.82 billion. The consensus estimate had been for earnings of $1.65 per share, with a “whisper number” of $1.66. Analysts expected $17.74 billion in revenues.

    Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share.

    Johnson & Johnson stock, however, was unfazed. Analysts had become accustomed to JNJ beating earnings estimates, and this upside surprise was the smallest since last December.

    Though it is twice the company’s newly raised dividend of 80 cents per share.

    Humira in Its Sights

    In its earnings release, Johnson & Johnson acknowledged that pharmaceutical products are the star of its show, with sales up 9.2% over a year ago. Cancer drugs and medicines heavily advertised on TV — such as Xarelto, an anti-coagulant whose ads starred the late Arnold Palmer, and Stelara, an immunosuppressant currently advertised for treatment of psoriasis, but recently approved for treatment of Crohn’s Disease — helped the cause.

    The FDA approval on Crohn’s disease is likely to hike the ad budget for Stelara. It will now compete more directly with Humira from AbbVie Inc (NYSE:ABBV), which generated $14 billion in sales in 2015 as a treatment for Crohn’s and rheumatoid arthritis.

    Johnson & Johnson also has another rheumatoid arthritis drug, sirukumab, going through the regulatory process.

    In addition to being heavily advertised, drugs to cure autoimmune diseases like Crohn’s, psoriasis and rheumatoid arthritis continue to be a key focus of research. So a business risk is that they will be replaced by better drugs before their patents expire.
    

    Thus immunosuppressant drugs such as Humira, Stelara and Otezla from Celgene Corporation(NASDAQ:CELG) are in heavy ad rotation to generate sales quickly, despite the fact that since the drugs can be approved for treatment of several conditions, there is considerable market confusion. The conditions they treat are often more implied than stated, since it’s possible they could be used to treatment other conditions that consumers may see as unrelated.

    This confusion demonstrates another risk for these drugs: the possibility that a new Clinton Administration may push either to instill greater price competition or controls on advertising to lower costs.

    Without Drugs, JNJ Stock Offers No Growth

    Outside the pharmaceutical business, JNJ stock is a slow-growth or no-growth prospect. Its popular consumer brands — products like baby powder and shampoo — of $3.3 billion were down 1.6% against the prior year, and sales of its medical devices, $6.6 billion, increased just 1.1%.

    The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE:ABT), for $4.325 billion, completed during the quarter, will help device sales going forward. That company recently launched a balloon dilation treatment for expanding the eustachion tube that runs between the ear and the mouth.

    JNJ stock advanced over 15% in price so far this year, despite the fact that most analysts have it rated only as a hold, due to its single-digit growth.

    This is the kind of company that investors can buy and hold if they don’t care to read stories like this one.

    Return to headline | Return to top

35. Johnson & Johnson (JNJ) Beats on Q3 Earnings, Revenues

    Oct 18, 2016 | Zack’s Equity Research

    Johnson & Johnson (JNJ - Analyst Report) ), the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.

    However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. JNJ also had issues with its consumer segment manufacturing facilities.

    In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.

    JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.88%. Estimates have however remained stable over the past 60 days.

    Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

    Earnings Beat: JNJ beat on third quarter earnings - the company reported EPS of $1.68 while our consensus called for EPS of $1.65.

    Revenues Beat: Revenues were above expectations as well. Johnson & Johnson posted revenues of $17.82 billion, compared to our consensus estimate of $17.72 billion.

    Ups Guidance: J&J upped its 2016 earnings guidance to $6.68 - $6.73 compared to $6.63 - $6.73 previously. The revenue guidance was maintained in the range of $71.5 billion - $72.2 billion.

    Stock Price Impact: Shares rose 0.43% in pre-market trading.

     

    Return to headline | Return to top

36. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results

    Oct 18, 2016 | The Cerbat Gem

    By Scott Moore

    Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday. The company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.66 by $0.02. The business had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%.

    Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. The company has a 50 day moving average of $118.71 and a 200-day moving average of $117.56. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The firm has a market cap of $324.17 billion, a PE ratio of 22.08 and a beta of 0.62.

    Several equities analysts have issued reports on JNJ shares. Barclays PLC reaffirmed an “overweight” rating and set a $125.00 price objective (up from $120.00) on shares of Johnson & Johnson in a report on Sunday, July 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Jefferies Group increased their price objective on shares of Johnson & Johnson from $109.00 to $113.00 and gave the company a “hold” rating in a report on Thursday, July 14th. Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, July 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $132.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 20th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $120.20.

    In other news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.

    Several hedge funds and other institutional investors have recently made changes to their positions in JNJ. Horizon Investments LLC increased its stake in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock worth $285,000 after buying an additional 8 shares during the period. Lbmc Investment Advisors LLC increased its stake in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $457,000 after buying an additional 16 shares during the period. Kinsight LLC increased its stake in Johnson & Johnson by 0.5% in the second quarter. Kinsight LLC now owns 3,891 shares of the company’s stock worth $472,000 after buying an additional 21 shares during the period. Greenwich Wealth Management LLC increased its stake in Johnson & Johnson by 1.1% in the second quarter. Greenwich Wealth Management LLC now owns 2,494 shares of the company’s stock worth $303,000 after buying an additional 27 shares during the period. Finally, Northeast Financial Consultants Inc increased its stake in Johnson & Johnson by 0.3% in the second quarter. Northeast Financial Consultants Inc now owns 14,992 shares of the company’s stock worth $1,819,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

    Johnson & Johnson Company Profile

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

37. Worth Watching Stock: Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | News Oracle

    By Adam Smith

    Johnson & Johnson (NYSE:JNJ) will report its next earnings on 18-Oct-16. The company reported the earnings of $1.74/Share in the last quarter where the estimated EPS by analysts was $1.68/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 3.6%.

    Many analysts are providing their Estimated Earnings analysis for Johnson & Johnson and for the current quarter 19 analysts have projected that the stock could give an Average Earnings estimate of $1.65/share. These analysts have also projected a Low Estimate of $1.59/share and a High Estimate of $1.75/share.

    In case of Revenue Estimates, 19 analysts have provided their consensus Average Revenue Estimates for Johnson & Johnson as 17.74 Billion. According to these analysts, the Low Revenue Estimate for Johnson & Johnson is 17.52 Billion and the High Revenue Estimate is 17.98 Billion. The company had Year Ago Sales of 17.1 Billion.

    These analysts also forecasted Growth Estimates for the Current Quarter for JNJ to be 10.7%. They are projecting Next Quarter growth of 9.7%. For the next 5 years, Johnson & Johnson is expecting Growth of 6.52% per annum, whereas in the past 5 years the growth was 6.33% per annum.

    Some buy side analysts are also providing their Analysis on Johnson & Johnson, where 3 analysts have rated the stock as Strong buy, 7 analysts have given a Buy signal, 13 said it’s a HOLD, 0 reported it as Underperform and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

    When it comes to the Analysis of a Stock, Price Target plays a vital role. 20 Analysts reported that the Price Target for Johnson & Johnson might touch $142 high while the Average Price Target and Low price Target is $124.5 and $81 respectively.

    To analyze a stock, one should look for Upgrades and Downgrades of a stock. Johnson & Johnson got Initiated on 20-May-16 where investment firm Standpoint Research Initiated the stock to Sell.

    Johnson & Johnson closed its last trading session at $117.56 with the gain of 0.79%. The Market Capitalization of the company stands at 326.1 Billion. The Company has 52-week high of $126.07 and 52-week low of $94.28. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -0.03% where SMA50 and SMA200 are -0.75% and 5.67% respectively. The Company Touched its 52-Week High on Jul 20, 2016 and 52-Week Low on Jan 21, 2016.

    The Relative Volume of the company is 1.15 and Average Volume (3 months) is 6.06 million. Johnson & Johnson P/E (price to earnings) ratio is 22.07 and Forward P/E ratio of 16.66.

    The company shows its Return on Assets (ROA) value of 11.1%. The Return on Equity (ROE) value stands at 20.9%. While it’s Return on Investment (ROI) value is 14.7%.

    Return to headline | Return to top

38. Johnson & Johnson (JNJ) Releases FY16 Earnings Guidance

    Oct 18, 2016 | Daily Political

    By Jeff Wilder

    Johnson & Johnson (NYSE:JNJ) updated its FY16 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $6.68-6.73 for the period, compared to the Thomson Reuters consensus estimate of $6.69. The company issued revenue guidance of $71.5-72.2 billion, compared to the consensus revenue estimate of $72.14 billion.

    A number of analysts have weighed in on the company. Zacks Investment Research upgraded Johnson & Johnson from a hold rating to a buy rating and set a $139.00 price target for the company in a report on Friday, August 5th. BMO Capital Markets reiterated an outperform rating and set a $132.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 20th. Deutsche Bank AG reiterated a hold rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. Vetr upgraded Johnson & Johnson from a sell rating to a hold rating and set a $124.21 price target for the company in a report on Monday, August 8th. Finally, BTIG Research restated a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $120.20.

    Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The company has a market cap of $324.17 billion, a PE ratio of 22.08 and a beta of 0.62. The company has a 50 day moving average of $118.71 and a 200-day moving average of $117.56.

    Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.03. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same period in the previous year, the business posted $1.49 EPS. The business’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.

    In related news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.

    A number of institutional investors have recently bought and sold shares of JNJ. Horizon Investments LLC boosted its position in Johnson & Johnson by 0.3% in the second quarter. Horizon Investments LLC now owns 2,349 shares of the company’s stock worth $285,000 after buying an additional 8 shares in the last quarter. Lbmc Investment Advisors LLC boosted its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $457,000 after buying an additional 16 shares in the last quarter. Kinsight LLC boosted its position in Johnson & Johnson by 0.5% in the second quarter. Kinsight LLC now owns 3,891 shares of the company’s stock worth $472,000 after buying an additional 21 shares in the last quarter. Greenwich Wealth Management LLC boosted its position in Johnson & Johnson by 1.1% in the second quarter. Greenwich Wealth Management LLC now owns 2,494 shares of the company’s stock worth $303,000 after buying an additional 27 shares in the last quarter. Finally, Northeast Financial Consultants Inc boosted its position in Johnson & Johnson by 0.3% in the second quarter. Northeast Financial Consultants Inc now owns 14,992 shares of the company’s stock worth $1,819,000 after buying an additional 40 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

    Johnson & Johnson Company Profile

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

39. What To Make Of Johnson & Johnson At $118 In The Wake Of Q3 Results

    Oct 18, 2016 | Seeking Alpha

    By Alessandro Pasetti

    Summary
    

    Q3 results released today confirmed trailing trends.
    

    JNJ raised guidance for adjusted earnings.
    

    Its pharmaceutical operations are growing strongly.
    

    So, are shareholders in a sweet spot?
    

    The third-quarter results of Johnson & Johnson (NYSE:JNJ), which were released today, suggest that shareholders are in a sweet spot. Or are they?
    

    1H16 Performance
    

    Before delving into third-quarter figures, it's worth looking at the headline numbers in the first half of the year.
    

    Recent quarterly trends, confirmed today, demonstrate that JNJ is a stable business and its stock an outstanding yield play; its main financial metrics were in good order earlier this year, as the two following tables indicate.
    

    On an aggregate basis, it turned over almost $36bn in the first half of 2016, carefully managing direct and indirect costs of production, yet net reported earnings dropped despite a more favorable tax rate. In the first half, one-off items and charges weighed on the bottom line on a reported basis, and had the bears talking of diminished earnings power.
    

    Today, however, JNJ announced sales of $17.8bn for the third quarter, up 4.2% year-on-year, which was a respectable performance.
    

    While it maintained its annual sales guidance of $71.5bn to $72.2bn, it raised the low-end of its adjusted earnings guidance to $6.68-$6.73 per share from $6.63-$6.73 per share previously. The table below shows its P&L in the first half of the year...
    

    .... while in the table below, you'll see how JNJ has fared in the first nine months, with its reported earnings up 5.1% to $4.55 on a diluted basis. 
    

    On the bright side, its rock-solid balance sheet did not contain any nasty surprise in the first half of the year, and likely it will not cause any headaches when full third-quarter disclosure comes with the 10-Q.
    

    Working capital management arguably deserves some attention, first-half figures showed, but cash flows from investing also proved that JNJ can swiftly act both to preserve a falling operating cash flows and to protect surging dividends and buybacks.
    

    It net cash position, at around $15bn at the end of the first half, testified to its strength and I do not expect any material swings, on a comparable basis, at the end of the third quarter.
    

    Expectations and Q3 Results
    

    Undoubtedly, quarterly results confirmed today that JNJ is on track to deliver earnings per share above $6 and dividends per share of $3.15, which implies a conservative, forward payout ratio of 52.5%.
    

    On this basis, its shares are fairly priced, given a yield that is consistent with its previous levels in recent years, despite a lower share price back then.
    

    Yesterday, I said that under certain circumstances JNJ stock could hit a lower valuation, but yield-starved investors may well argue that it is fairly priced and could rally through to 2017, notwithstanding possible rates hikes.
    

    As competition intensifies from Pfizer (NYSE:PFE), its pharmaceutical business reported a very solid growth rate, although the performance of the reminder of its assets portfolio was more subdued -- and that is one thing to consider for investors looking to add to their existing exposure.
    

    In this context, the focus is on the outlook for its core pharmaceutical business, which stands out as a chief value-driver.
    

    In the third-quarter release, president and chief executive Alex Gorsky noted that:
    

    Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1bn."
    

    Yet its consumer divisions also drew my attention.
    

    What do you make of it? Any feedback would be gratefully received.
    

    Risks
    

    For the record, the share price was little changed in pre-market trade on Tuesday, likely because consumer and medical devices activities are not exactly on a roll.
    

    Since the departure of William Weldon -- the worst chief executive of 2011, according to The New York Times -- product recalls have not been a problem, while a very conservative capital structure has pleased shareholders so far. The bulls, of course, can also point to a wise capital deployment strategy over the past few years, which benefited shareholders.
    

    Under a worst-case scenario, however, there remain a few risks stemming from a top-down approach; of course, the damage could be contained if JNJ's core pharma division continues to deliver.
    

    Still, I am not going to open a full position at these prices.
    

    Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
    

    I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Return to headline | Return to top

40. Johnson & Johnson Remains Flat Despite Earnings Beat

    Oct 18, 2016 | 24/7 Wall Street

    By Chris Lange

    Johnson & Johnson (NYSE: JNJ) released its third-quarter earnings report before the markets opened on Tuesday. The company said that it had $1.68 in earnings per share (EPS) and $17.8 billion in revenue. The third-quarter from last year reportedly had $1.49 in EPS and revenue of $17.1 billion. Thomson Reuters consensus estimates had called for EPS of $1.65 and $17.74 billion in revenue.

    Domestic sales increased 6.7%. International sales increased 1.5%, reflecting operational growth of 1.7% and a negative currency impact of 0.2%. However, excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 5.9%, domestic sales increased 7.3% and international sales increased 4.2%.

    During the quarter, a definitive agreement was announced to acquire Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash.

    Johnson & Johnson maintained its sales guidance for the full-year 2016 of $71.5 billion to $72.2 billion. Additionally, the company increased its adjusted earnings guidance for full-year 2016 to the range of $6.68 to $6.73 per share. The consensus estimates for the full year were $6.69 in EPS and $72.16 billion in revenue.

    Alex Gorsky, board chair and chief executive, commented:
    

    Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” “Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care.

    Shares closed Monday at $118.49, with a consensus analyst price target of $124.50 and a 52-week trading range of $94.28 to $126.07. After the report was released, shares remained relatively flat in early trading indications Tuesday.

    Return to headline | Return to top

41. Johnson & Johnson (JNJ) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

    Oct 18, 2016 | Community Financial News

    By Trent Williams

    Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.66 by $0.02. The company earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%.

    Johnson & Johnson (NYSE:JNJ) opened at 118.49 on Tuesday. The company’s 50 day moving average price is $118.71 and its 200-day moving average price is $117.56. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The stock has a market cap of $324.17 billion, a price-to-earnings ratio of 22.08 and a beta of 0.62.

    In related news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

    A number of hedge funds have recently made changes to their positions in JNJ. Banced Corp raised its position in shares of Johnson & Johnson by 10.9% in the second quarter. Banced Corp now owns 7,644 shares of the company’s stock worth $714,000 after buying an additional 754 shares in the last quarter. American Century Companies Inc. raised its position in shares of Johnson & Johnson by 24.5% in the second quarter. American Century Companies Inc. now owns 7,061,430 shares of the company’s stock worth $856,551,000 after buying an additional 1,388,010 shares in the last quarter. Wedge Capital Management L L P NC raised its position in shares of Johnson & Johnson by 12.9% in the second quarter. Wedge Capital Management L L P NC now owns 422,349 shares of the company’s stock worth $51,231,000 after buying an additional 48,208 shares in the last quarter. Exane Derivatives raised its position in shares of Johnson & Johnson by 305.4% in the second quarter. Exane Derivatives now owns 2,027 shares of the company’s stock worth $246,000 after buying an additional 1,527 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its position in shares of Johnson & Johnson by 5.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 291,845 shares of the company’s stock worth $35,401,000 after buying an additional 14,552 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

    Several research analysts recently weighed in on the company. RBC Capital Markets reiterated an “outperform” rating and issued a $133.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann restated an “outperform” rating and set a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 20th. BMO Capital Markets restated an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Finally, Deutsche Bank AG restated a “hold” rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $120.20.

    About Johnson & Johnson

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

42. Johnson & Johnson (JNJ) Beats Estimates, Reports $1.68 EPS

    Oct 18, 2016 | Economic Calendar

    By Paul Rosenberg

    Johnson & Johnson (NYSE:JNJ) reported third-quarter results this morning, topping analyst estimates. The company reported adjusted earnings per share of $1.68 on $17.8 billion in revenues. This was an increase in revenues of 4.2% from the same quarter a year-ago. Analysts on average were looking for $1.66 EPS on $17.7 billion in revenues.
    

    Shares of JNJ are trading lower in early trade by 1.05% to $117.24.

    From the official earnings release: “Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business. With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” said Alex Gorsky, Chairman and Chief Executive Officer. “Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care.”

    Global consumer sales fell 1.6% to $3.3 billion from Q3 2015. Domestic sales saw an increase of 1.1%, while international sales fell 3.3%.

    Strong global pharmaceutical sales were a solid boost to earnings, rising 9.2% to $8.4 billion from a year-ago. Domestic sales were the main contributor with an increase of 11.8%, while international sales grew 5.4%.

    During the third quarter, Johnson and Johnson announced it would acquire Abbott Medical Optics from Abbott Laboratories for $4.325 billion in cash.

    The share performance of JNJ has been strong over all time periods. The stock reached a record high in July at over $126 per share. For the year, JNJ stock is up over 14%.

    Return to headline | Return to top

43. Stay calm, investors. J&J has a 'readiness plan' in place for Remicade biosim launch

    Oct 18, 2016 | FiercePharma

    By Arelen Weintraub

    Just yesterday, one of the biggest potential threats to Johnson & Johnson’s ($JNJ) top line moved closer to reality as Pfizer ($PFE) announced it will begin shipping a biosimilar version of J&J’s blockbuster Remicade in late November. But executives of J&J, who had been insisting they wouldn’t face biosimilar competition this year, weren’t fazed during the company’s third-quarter earnings release today, even though Remicade’s stand-out performance clearly raises questions about how healthy the top line will be if it takes a hit from Pfizer’s rival product.

    Remicade, used to treat autoimmune disorders like rheumatoid arthritis, hauled in $1.8 billion during the quarter, driving a 9% overall rise in J&J’s prescription drug sales to $8.4 billion. J&J’s U.S. prescription drug sales soared 12%. Its overall revenues came in at $17.82 billion, beating the average analyst estimate of $17.71 billion, according to Zacks.

    During a conference call with analysts after the earnings release, Joaquin Duato, worldwide chairman of J&J’s pharmaceuticals group, said the company is gearing up for Pfizer’s Remicade rival with a “focused biosimilar readiness plan.” That plan includes trying to delay Pfizer’s launch via an appeals process, and sending out its sales reps to preach the superiority of Remicade’s scientific track record and J&J’s extensive patient-assistance program. Remicade’s “significant long-term safety data, strong advocacy for patients and clear physician preference means that 70% of patients who are stable on Remicade are highly unlikely to switch,” Duato said.

    Duato added that in markets like Australia and Brazil, where a Remicade biosimilar has been available for some time, J&J’s drug still holds a market share of more than 90%. The company also has an aggressive R&D strategy that has already produced new immunology products poised to compete with biosimilars of old blockbusters, he said. He pointed to the company’s rheumatoid arthritis treatment Simponi, which brought in worldwide sales of $481 million during the quarter, up 26.6% from the same quarter last year.

    J&J had a surprisingly good quarter overall, to be sure. The company’s net income after amortization and special items soared 12% to $4.27 billion ($1.68 per share), beating estimates by 3 cents. Its medical device sales nudged up 1% to $6.16 billion. The biggest weak spot was J&J’s consumer health business, where sales dropped nearly 2% to $3.26 billion.
    

    Analysts expect that the launch of Pfizer’s Remicade biosimilar, called Inflectra (infliximab-dyyb), will have some impact on J&J’s 2017 sales, though it’s not yet clear how big a hit the company will take. Leerink Partners analyst Danielle Antalffy released a note pointing out that Inflectra will launch at a relatively low 15% discount. Antalffy wrote, “our initial thoughts are that JNJ will be able to absorb a similar price cut and retain a good portion of Remicade sales, thus making downside to our current 2017 estimates limited.”

    During the earnings call, J&J CFO Dominic Caruso addressed concerns about whether the company can maintain its growth in 2017 by predicting that its prescription drug sales will expand at a similar rate to what the company is seeing this year, and that performance in both medical devices and consumer health will improve. "We continue to pursue significant growth opportunities in terms of both penetration within existing indications, and planned line extensions," Duato added, which will help buoy that growth rate.

    In addition to charting strong performance for Simponi, the company saw sales of its blood thinner, Xarelto, rise 15% during the quarter to $529 million. Sales of Stelara to treat psoriasis jumped 33% to $814 million, and the haul for cancer drug Imbruvica nearly doubled to $349 million.

    J&J raised its earnings guidance for the year slightly, from $6.63 to $6.73 per share to $6.68 to $6.73. Caruso promised during the earnings call to provide more color on the company’s 2017 expectations in January. J&J’s shares opened down nearly 2% to $116.18 in morning trading.

    - here’s J&J’s earnings release
    - get Pfizer’s launch release here
    - read more at the Associated Press

    Return to headline | Return to top

44. The Statistics Don’t Lie: Johnson & Johnson (NYSE:JNJ) Earnings Preview

    Oct 18, 2016 | Voice Registrar

    By Claudia Dawson

    Johnson & Johnson (NYSE:JNJ) got boosted by 0.79 per cent through the trading floor to reach at $118.49 as its next quarterly earnings report date is October 18, 2016. JNJ stock is keeping its price in the $117.5 to $118.55 range before earnings are released. Let’s take a deeper look at the December 2016 earnings forecast, particularly something that investors should watch closely when picking stocks. Earnings per share for the most recently closed financial statements is expected to come in at $1.58/share with $18.39B in revenue.

    Johnson & Johnson Approaching Earnings & Historical Perspective
    

    After approaching fiscal quarter results, all eyes will be on the prospects for the subsequent reporting quarter (March 2017). Analysts, on average, forecast Johnson & Johnson to show profit of $1.77 per share (EPS) on revenue of $18.35B. The EPS consensus range is $1.69-$1.87 on revenue forecast of between $18.19B and $18.52B.
    

    From the historical earnings perspective, Johnson & Johnson (JNJ) managed to surpass quarterly earnings per share estimates in 12 of the trailing three fiscal years, and has a positive trend with an average surprise of 100%. Last time the company reported, Johnson & Johnson generated $1.74 in earnings per share, surpassing the consensus estimate of $1.68. Revenues hit $18.48B in the June 2016 quarter, which was above the analysts’ $17.98B projection. If we dig further into historical earnings data, the March 2016 quarter the company recorded a net $17.48B revenue with earnings per share of $1.68. Wall Street had anticipated $17.48B and $1.65, respectively. For comparison, there was a revenue of $17.81B and EPS of $1.44 in the December 2015 period.

    Johnson & Johnson (NYSE:JNJ) Analyst Insights

    The buoyancy in the outlook of Johnson & Johnson (JNJ) is getting weaker by the somewhat negative sentiment (2.5 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Overweight. Standpoint Research has been covering shares of JNJ, so it’s most recent view is worth analyzing. In a research note issued on May 20, 2016, analysts at Standpoint Research issued its first rating on the stock at Sell. Another noteworthy analyst activity was recorded on March 14, 2016. Goldman analysts lifted the stock to Neutral from Sell.

    Johnson & Johnson is trading up 28.5 per cent versus 12-month low of $94.28 and stands -5.39 per cent lower from its 1-year peak of $126.07. The consensus price target (PT) of $124.5 means that the Company shares are likely to increase by 5.07 per cent in the short run. The sell-side target prices range from $81 to $142. In the last month the stock has moved in price 0.2 per cent, with a one year change of 24.08%. The last trading session volume compares with the 6.06M average and market worth floats around $321.63B.

    Return to headline | Return to top

45. J&J Sees No Obstacles From Absence of Tax Reform

    Oct 18, 2016 | The Street

    By Sarah Pringle

    Johnson & Johnson's  (JNJ)  CFO Dominic Caruso told investors on a Tuesday morning conference call that its future dealmaking possibilities don't rely on the passage of international tax reform, though he did say he views there being more bipartisan support for such legislation than in the past. At the same time, the exec voiced his opposition to the California drug pricing ballot measure known as Prop 61.

    Besides having plenty borrowing capacity, Caruso said on the company's third quarter earnings call that J&J has had the benefit of being able to structure transactions by effectively using foreign earnings kept abroad in an effective manner. That cash would be subject to tax on repatriation, but U.S. companies can borrow against it.

    "Whether or not we do a major transaction would not be dependent on waiting for international tax reform," Caruso told investors on the call. 

    Still, when asked about the likelihood of tax reform, Caruso did say that from his perspective, the post-election climate is more positive than it has been in the last year or so. 

    If the company did look to do a transformative acquisition, it would likely be to add another leg to its existing five therapeutic areas of focus: oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolism. 

    While J&J has largely focused on building out its existing five therapeutic areas through collaborations, licensing transactions and other partnerships, Caruso stated that an "acquisition-type strategy" would likely be pursued should it deem another therapeutic area important. 

    J&J has already expressed the growth it sees in ophthalmology, agreeing in September to fork out about $4.3 billion in cash to acquire Abbott Medical Optics. 

    Within its consumer business, J&J's primary focus will be expansion into international and emerging markets, and particularly in Asia, while it will eye strong brands, over-the-counter medications, and assets in the beauty space, the CFO said. 

    On the medical device front, Caruso said company will continue to look for additional bolt-ons to its existing orthopedics and general surgery businesses. Other areas within cardiovascular seem attractive, though he emphasized that J&J will remain disciplined about deals considered from a valuation perspective.

    On other matters of political referendum, executives of the New Brunswick, N.J.-based healthcare giant expressed their opposition to California ballot measure Proposition 61, a drug price standards initiative designed to restrict the amount any state agency could pay for drugs, tied to the price paid by the U.S. Department of Veterans Affairs.

    "We would prefer to have pricing more related to outcomes," Caruso said, emphasizing the company's support for evidence-based pricing. 

    Joaquin Duato, J&J worldwide chairman, pharmaceuticals, added that Prop 61 would be difficult to operationalize and would create access to barriers, calling it a "misguided action".

    According to Ballotpedia, polls indicate that support for the law sits at about 69.5%. Prop 61 supporters include Sen. Bernie Sanders and the AIDS Healthcare Foundation, and could potentially be the ballot measure with the most money spent on it ever in California's history, according to Ballotpedia.

    J&J shares retreated about 2.3% to $115.76 during Tuesday's trading session, even while the company reported better-than-anticipated earnings results. 

    The company posted earnings per share of $1.68 on revenue of $17.8 billion, ahead of the Street's projections of earnings per share of $1.65 on revenue of $17.74 billion. 

    While the company defended its blockbuster rheumatoid arthritis drug Remicade drug on Tuesday's conference call, the product does face competition. Notably, Pfizer PFE just announced its plans to launch a cheaper biosimilar version of Remicade. 

    Return to headline | Return to top

46. Johnson & Johnson Under Heavy Pressure

    Oct 18, 2016 | The Street

    By Gary Morrow

    Shares of Johnson & Johnson (JNJ)  were getting hit hard Tuesday morning despite a strong earnings report before the bell.  The stock is off 2.3% on heavy trade and is taking out a very solid support zone in the process.  This nasty breakdown has further to go.

    During the eight weeks prior to this morning's earnings-inspired selloff Johnson & Johnson had been trading in a very narrow range.  This healthy consolidation followed the August pullback while holding a key support zone between $118.00 and $117.00. Johnson & Johnson was building a solid base for a new rally leg but with today's clear break of $117.00 a great deal of overhead pressure is building dramatically.  In the near term this will push shares lower.

    Johnson & Johnson will soon test the May high.  This area, near $115.00, is the next support level but I expect it to give way.  More likely is a drift down to the 200 day moving average at $113.35. Johnson & Johnson has not tested this key long term indicator since January.  It also marks a 1/3 retracement of the stock's entire 2016 range.  If the stock can regain its footing here a very low risk entry opportunity will develop for patient bulls.  On the downside, a close below $112.00 would indicate a more prolonged bottoming process is ahead.

    Return to headline | Return to top

47. Competition Is Concerning for Johnson & Johnson

    Oct 18, 2016 | Morningstar

    By Damien Conoves

    Johnson & Johnson (JNJ) reported second-quarter results slightly ahead of both our and consensus expectations, but we don’t expect any major changes to our $112 fair value estimate, suggesting the stock looks slightly overvalued. We continue to believe the market is not incorporating enough declines on several complex drugs, including Concerta (2017-18 expected generic competition), Risperdal Consta (2017), Velcade (2016-19), Remicade (2016-18), and Invega Sustenna (2018). While the majority of these drugs will face slower declines then typical small molecules, we project more rapid declines than consensus. For the company’s largest drug, Remicade, we expect 2020 sales of below $4 billion relative to consensus expectations of $5.3 billion. While the magnitude of these losses is concerning, JNJ’s breadth of businesses helps reinforce its moat during times of excessive patent losses.

    In the quarter, total operational sales increased 6% year over year, driven by robust drug sales (up 11%), but upcoming generic and biosimilar pressures will likely slow this growth despite solid new drug launches. Strong growth in immunology and oncology drove the results. Further, immunology drug Stelara posted 33% growth and while the drug will likely lose market share to better psoriasis drugs, including new IL-17 and IL-23 therapies, the drug’s new indication in Crohn’s disease will likely lead to relatively stable growth. In oncology, the recent launch of Imbruvica continues to trend well, and the addition of another blood cancer drug, Darzalex, should help offset generic competition to Zytiga and Velcade expected over the next two years.

    Outside of the drug group, the consumer and device segments posted close to 3% growth after adjusting for inventory changes. We don’t see organic growth increasing much beyond this level of growth, which may lead to more acquisitions in these areas. However, we do expect efficiency improvements to drive earnings contributions for these groups.

    Return to headline | Return to top

48. Stock Jumping Abnormally High: Johnson & Johnson (NYSE:JNJ)

    Oct 18, 2016 | Facts Reporter

    By Jay Jacobs

    Johnson & Johnson (NYSE:JNJ) belonging to the Medical sector has surged 0.79% and closed its last trading session at $118.49.

    The Company is expected to report its next EPS on Oct 18 BMO. Currently, the stock has a 1 Year Price Target of $124.5.

    The consensus recommendation, according to Zacks Investment research, is 2.22. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.11 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.22 and 2.29 respectively.

    Johnson & Johnson on 9/30/2016 reported its EPS as $1.74 with the analysts projecting the EPS of the stock as $1.68. The company beat the analyst EPS Estimate with the difference of $0.06. This shows a surprise factor of 3.6%.

    Many analysts have provided their estimated foresights on Johnson & Johnson Earnings, with 19 analysts believing the company would generate an Average Estimate of $1.65. Whereas they predicted High and Low Earnings Estimate as $1.75 and $1.59 respectively. While in the same Quarter Previous year, the Actual EPS was $1.49.

    Analysts are also projecting an Average Revenue Estimate for Johnson & Johnson as $17.74 Billion in the Current Quarter. This estimate is provided by 19 analysts. The High Revenue estimate is predicted as 17.98 Billion, while the Low Revenue Estimate prediction stands at 17.52 Billion. The company’s last year sales total was 17.1 Billion.

    For the Current Quarter, the growth estimate for Johnson & Johnson is 10.7%, while for the Next Quarter the stock growth estimate is 9.7%. In the past 5 years, the stock showed growth of 6.33% per annum. While for the next 5 years, the growth estimate is 6.52%.

    The Company got Initiated by Standpoint Research on 20-May-16 to Sell.

    Insider Trades for Johnson & Johnson show that the latest trade was made on 25 Jul 2016 where Caruso (Dominic J), the Chief Financial Officer completed a transaction type “Sell” in which 41146 shares were traded at a price of $125.01.

    Over the period of 6 months, Insider Purchases show a total of 2 transaction in which 5000 shares were traded.

    20 analysts projected Price Targets for Johnson & Johnson. The analysts believe that the company stock price could grow as high as $142. The Low Price target projection by analysts is $81 and the Mean Price Target is $124.5.

    Johnson & Johnson (NYSE:JNJ) has the market capitalization of $326.1 Billion. The company rocked its 52-Week High of $126.07 on Jul 20, 2016 and touched its 52-Week Low of $94.28 on Jan 21, 2016. The stock has Return on Assets (ROA) of 11.1 percent. Return on Equity (ROE) stands at 20.9% and Return on Investment (ROI) of 14.7 percent.

    The stock is currently showing YTD performance of 17.8 Percent. The company has Beta Value of 0.75 and ATR value of 1.3. The Weekly and Monthly Volatility stands at 1.31% and 1.02%.

    Company profile:

    Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.

    Return to headline | Return to top

49. Pfizer loads up for Remicade biosim launch, with $4.5B J&J brand in its sights

    Oct 18, 2016 | FiercePharma

    By Eric Sagonowsky

     Pfizer’s U.S. biosimilar assault on Johnson & Johnson’s star autoimmune med Remicade is set for go. Late Monday, Pfizer said it’ll begin shipping its Remicade biosimilar, Inflectra, late next month.

    Pfizer says it will list Inflectra at a 15% discount to Remicade’s wholesale acquisition cost, or $946.28 per 100-mg vial, according to a company spokesperson, “to offer immediate relief in this high-cost area.”

    That's the list price, however, and payers are eager to strike deals on biosims as a way to save money on high-cost biologic drugs like Remicade, which delivered $4.5 billion in sales to J&J last year. And though Remicade biosims launched in Europe at fairly reasonable discounts, they quickly gobbled up market share from Merck & Co., which markets the med in that region.

    J&J, meanwhile, says it's prepared for the fight. The “U.S. commercial team is ready for a potential biosimilar launch,” Joaquin Duato, pharma group chairman, said on the company’s Q3 conference call Tuesday. It’s already an “extremely competitive” market on price, he said, and J&J intends to develop “innovative contracts” to “utilize the full breadth” of its portfolio.

    “We feel well prepared to face the biosimilar and as (CFO) Dominic (Caruso) said we are convinced that we will continue to grow our business in the face of biosimilar competition,” Duato said on the call.

    J&J’s Remicade sells for $1,113 per vial before discounts, or $28,945 per year for the average patient, according to a company spokesperson. But its average selling price is 30% cheaper following "significant" discounts and rebates.

    Pfizer is moving forward despite the fact that the companies haven’t resolved a Remicade patent dispute. In August, a U.S. district judge struck down a key patent on the drug, prompting J&J to appeal. The New Jersey company said it considered any launch by Pfizer before the resolution “at-risk," which could put the New York pharma on the hook for triple damages if found in violation of Remicade patents.

    Recently announced formularies show that U.S. payers are aiming to squeeze savings out of big drug-spending categories by adopting biosimilars. CVS Health, for one, has opted to go with Novartis’ biosimilar of Amgen brand Neupogen, Zarxio, and Eli Lilly and Boehringer Ingelheim’s copy of Sanofi’s basal insulin Lantus, Basaglar.

    Pfizer’s discount is one that Credit Suisse analyst Vamil Divan called “reasonable” in a note to clients Tuesday. Divan said J&J investors will likely welcome the “clarity” on the Remicade biosim threat.

    Still, with its $4 billion-plus in annual sales, Remicade is a key contributor for the New Jersey drug giant, and the fact that it’s facing biosimilar competition could bring some discomfort, particularly if Merck's experience is any guide. The company's decrease in brand sales was swift and significant in Europe; in its most recent earnings announcement, Merck reported a 26% decrease in Remicade sales on the continent. Inflectra has been available in Europe since early last year.

    In its efforts to fend off competition, Merck reduced the cost of Remicade in the U.K., an approach J&J could consider in the U.S., but one that would still erode sales.

    Return to headline | Return to top

50. Johnson & Johnson Reported Better-than-Expected Earnings Boosted by Pharmaceuticals

    Oct 18, 2016 | Financial Buzz

     Johnson & Johnson (NYSE:JNJ) reported its financial results of the third quarter of 2016, announcing better-than-anticipated sales and earnings, and raising the forecasts for the full-year 2016.

    According the report, sales of J&J for the third quarter increased 4.2% to $17.8 billion from the same period last year, which was above analysts’ estimate of $17.74 billion. Net earnings in the third quarter was $4.27 billion, increasing from $3.36 billion the same period last year. Diluted earnings per share was $1.53, which was up from $1.20 per share last year. In addition, adjusted earnings per share, excluding certain items, also increased to $1.68 per share, which was more than the previous expectation of $1.66 per share.

    For the full-year of 2016, the company kept the sales guidance of between $71.5 billion to $72.2 billion, and increased its guidance for adjusted earnings per share to $6.68 to $6.73 per share.

    According the Alex Gorsky, the Chief Executive of Johnson & Johnson, the satisfying results were driven by growth in pharmaceuticals business, and owing to the launch of new products and the strength of core businesses.

    “With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” said Alex.

    However, J&J also meet challenges. Other segments of the company are not as strong as pharmaceuticals business. In the latest quarter, sales of consumer health products dropped 1.6% to $3.26 billion. In addition, the strengthening U.S. dollar and weakness in emerging markets also threaten the company.

    In respond to the announcement of Pfizer Inc on Monday, which said Pfizer would start selling a biosimilar version of blockbuster rheumatoid-arthritis treatment Remicade late this year at a lower price, J&J said that it would fight the launch of biosimilar products.

    Return to headline | Return to top

51. Johnson & Johnson (JNJ) 'Tracking Higher Expectations,' CFO Caruso Says

    Oct 18, 2016 | The Street

    By Giovanni Bruno

    Johnson & Johnson (JNJ) reported better-than-expected 2016 third-quarter earnings results before the market open on Tuesday. The healthcare products company posted earnings of $1.68 per share on revenue of $17.8 billion. Analysts were projecting earnings of $1.65 per share on revenue of $17.74 billion.

    "Overall the results were very good and we're very proud. Strong sales growth and underlying sales growth, about 5.9% and very good earnings growth, 12.8%. We increased our guidance last quarter and now we're tracking to those higher expectations," Johnson & Johnson CFO David Caruso said during CNBC's"Squawk Box" Tuesday morning.

    Although the company has reiterated its expectations to achieve full-year guidance, Johnson & Johnson does face some potential headwinds, namely biosimilar competition.

    Recently, drug manufacturer Pfizer (PFE) announced it would be introducing a biosimilar version of Johnson & Johnson's Remicade drug at a 15% discount.

    Remicade is Johnson & Johnson's premier rheumatoid arthritis drug and its biggest seller at $5 billion in U.S. sales a year, according to Reuters.

    "We've said before, and we are going to reiterate today that our guidance for this year would not change regardless of biosimilar launches," Caruso noted.

    He added that Johnson & Johnson has had to face competition within this market before, that it intendeds to "defend intellectual property vigorously," and boasts a broad portfolio across the entire pharmaceutical business.

    Shares of Johnson & Johnson were lower in pre-market trading on Tuesday.

    Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

    The team rates Johnson & Johnson as a Buy with a ratings score of A-. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. The team feels its strengths outweigh the fact that the company has had sub par growth in net income.

    Return to headline | Return to top

52. Pfizer to launch cheaper version of J&J immune drug Remicade

    Oct 18, 2016 | The Village Suntimes

    By Jay Jacobs

     Inflectra, okayed by the U.S. Food and Drug Administration in April, was the second biosimilar to gain U.S. approval and the first copycat version of Johnson & Johnson's blockbuster anti-inflammatory drug Remicade.

    Biosimilars are near-copies of biologic drugs, which are very expensive injected medicines that are "manufactured" inside living cells, rather than by mixing chemicals together.

    In addition to rheumatoid arthritis Inflectra, like Remicade, is also approved to treat Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis and the spine condition ankylosing spondylitits.

    However, the company is set to face competition for Remicade in the United States. WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

    "Inflectra's 15 percent discount should provide enough of an incentive to help attract new patients. but probably won't be enough of a discount to entice stable patients to switch over", Weinstein said.

    The cost for Remicade varies, because the dosage depends on the patient's weight, the immune disorder being treated and whether the patient is beginning treatment or on a lower maintenance dose, but it's roughly $2,600 per month without insurance.

    Pfizer now holds exclusive rights to commercialize Celltrion's Remicade biosimilar in select markets, including the USA and Canada through a sales partnership between Pfizer-owned Hospira and Celltrion.

    Excluding special items, J&J earned $1.68 per share on revenue of $17.82 billion.

    Global device sales inched up 1.1 percent to $6.16 billion in the third quarter, while consumer product sales fell about 1.6 percent to $3.26 billion. Bu in the US, biosimilars have been delayed by the lengthy process of setting up rules for their approval, as well as lawsuits between drugmakers.

    Biosimilar drugs are close copies meant to provide savings compared with costly branded products. That could entitle the company to triple damages if Pfizer is found in court to have infringed Remicade patents.

    Remicade is known chemically as infliximab.

    The Pfizer drug, to be sold under the name Inflectra, is already available in Europe and other overseas markets.

    During the most recent period, sales of Remicade - one of J&J's top sellers - surged 18% world-wide, as the pharmaceutical business, the company's largest, continued to propel J&J.

    Return to headline | Return to top

53. Why Johnson & Johnson is Tanking

    Oct 18, 2016 | Barron’s

    By Ben Levisohn

    Johnson & Johnson (JNJ) did everything you could ask a company to do when it reported its third-quarter financial results today. It beat earnings forecasts; its sales easily topped the Street consensus; and it increased its guidance. Still, shares of Johnson & Johnson have dropped more than 2%. What gives? Leerink’s Danielle Antalffy explains:

    This morning, Johnson & Johnson continued the growth momentum the company has seen in recent quarters, delivering its 3rd consecutive quarter of organic sales growth now solidly in the mid-single-digit range even despite what is usually a seasonally weak quarter. Johnson & Johnson delivered EPS outperformance, reporting 3Q16 EPS of $1.68 (+12.8% y/y reported and as-adjusted ex. the impact of FX,acquisitions/divestitures, and Olysio) vs. us at $1.63 and the Street at $1.65. Sales of $17.82B (+4.2%, +4.3% ex. FX) came in well ahead of us and the Street at $17.550B and $17.74B, respectively. And organic sales growth of 4.3% came in nearly double our 2.3% projection. But upcoming generic Remicade competition in the U.S. — with Pfizer (PFE) announcing yesterday that it will launch at risk in late November — does add some uncertainty to the 2017 outlook and sustainability of this mid-single-digit growth profile going forward. In addition, while sales outperformed, both gross and operating margins came in below expectations, with EPS outperformance largely driven by non-operational items like tax rate and “other” income/expense. Because of this, upside to shares could be muted today despite what we believes is a continuation of an overall positive trend at JNJ in which the company is seeing: (1) Strong growth from both core and new Pharma product launches, which are the primary contributors of outperformance; and (2) A continued, seemingly sustainable rebound in core MD&D businesses like Cardiovascular, Ortho, and Surgery.

    And apparently, Johnson & Johnson said that it would compete on price with Pfizer, something the Financial Times characterized as a “price war.”

    Shares of Johnson & Johnson have dropped 2.1% to $115.97 at 11:38 a.m. today, while Pfizer has risen 0.9% to $32.79.

    Return to headline | Return to top

54. Pharma Boosts Johnson & Johnson Despite Falling Consumer Sales

    Oct 18, 2016 | Motley Fool

    By Dan Caplinger

    It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE:JNJ) isn't its most important business segment. Indeed, recently, consumer products have been the laggard for the healthcare conglomerate, and strength in the pharmaceutical business has been the key driver of overall growth for J&J. Coming into Tuesday's third-quarter financial report, J&J investors fully expected that those trends would continue, creating modest sales growth that would translate into bottom-line success. Johnson & Johnson's results were even stronger than anticipated, giving shareholders comfort that the healthcare giant is still moving forward. Let's take a closer look at Johnson & Johnson's latest results and what lies ahead for the company.J&J rides the pharma train higher

    Johnson & Johnson's third-quarter financials continued to build positive momentum for the healthcare conglomerate. Revenue climbed 4.3% to $17.82 billion, accelerating from last quarter's growth pace and topping the consensus forecast among investors. Adjusted net income rose 12% to $4.68 billion, and that produced adjusted earnings of $1.68 per share, beating what those following the stock had expected by $0.03 per share.

    As we've seen in several past quarters, the strength of Johnson & Johnson's overall business was concentrated in the pharmaceutical division. Pharma sales jumped 9% to $8.4 billion, rapidly approaching the 50% mark in terms of its total contribution to J&J's top line. Gains for medical devices were much smaller, rising 1.1% from year-ago levels, and the consumer division actually lost ground on the sales front with a 1.6% decline.

    One reason for the weakness in consumer sales was the strong U.S. dollar, which hit the division more strongly than the other two segments and reversed what would have been a slight 0.1% gain in currency-neutral revenue. Interestingly, both pharma and medical devices reported small boosts to sales from currency impacts. Domestic growth continued to be the biggest influence on Johnson & Johnson's sales, picking up 6.7% compared to a 1.5% rise for international revenue."" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" style="border: 0px currentColor; border-image: none; vertical-align: bottom;">

    Looking more closely at Johnson & Johnson's product lines, the company said that Listerine oral care and Aveeno skin care products were among the biggest positive contributors on the consumer front, although lower inventory levels in the U.S. held back growth. In pharma, new products like cancer-fighters Imbruvica and Darzalex showed strong growth, and existing treatments like psoriasis and arthritis drug Stelara and anti-inflammatories Simponi and Remicade also helped J&J grow. For the medical products segment, electrophysiology cardiovascular products, endocutters for advanced surgery, and Acuvue contact lenses in vision care were strong contributors to growth.Can Johnson & Johnson keep growing?

    CEO Alex Gorsky concentrated on the impact that pharma had on the company and its role in future success. "With a number of regulatory approvals, several new drug application submissions, and new breakthrough therapy designations from the FDA," Gorsky said, "we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion."

    Reflecting on its success, Johnson & Johnson also made some upward adjustments to its guidance for the year. The healthcare giant kept its sales projections stable at between $71.5 billion to $72.2 billion. However, it boosted the lower end of its previous earnings range by $0.05 per share, making its new guidance between $6.68 and $6.73 per share.

    One thing that could change pharma's dominance at the company is J&J's recent purchase of Abbott Medical Optics. Johnson & Johnson paid Abbott Laboratories (NYSE:ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. Given how well Acuvue has done for the medical device division at J&J, investors hope that the purchase will further leverage the power of that brand.

    Investors didn't respond very much to Johnson & Johnson's results, with the stock trading on either side of unchanged in pre-market trading after the announcement. In the long run, though, it's important that J&J continue to emphasize not only that its pharmaceutical division still has room to grow but also that it isn't neglecting the potential of its other businesses.

    10 stocks we like better than Johnson and Johnson
    When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* 

    David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Johnson and Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

    Return to headline | Return to top

55. Pay Close Attention to These Analyst Ratings: Johnson & Johnson (NYSE: JNJ), Church & Dwight Co. Inc. (NYSE: CHD)

    Oct 18, 2016 | Voice Registrar

    By Lewis Gonzalez

    Johnson & Johnson (NYSE:JNJ) went up 0.79% during trading on 10/17/2016, with the company’s shares hitting the price near $118.49. The stock had a trading capacity of 6.94M shares. The firm has a SMA 50 (Simple Moving Average) of $118.72 and a SMA 200-(Simple Moving Average) of $117.37. This appreciation has taken its market valuation to 326.10B. Shares registered one year high at $125.23 and the one year low of $92.21.

    Johnson & Johnson (NYSE:JNJ) Analyst Evaluation

    Johnson & Johnson (NYSE:JNJ) currently has mean rating of 2.50 while 7 analysts have commented the shares as ‘BUY’, 3 recommended as ‘OUTPERFORM’ and 13 commented as ‘HOLD’. The rating score is on a scale of 1-5 where 1 stands for strong buy and 5 stands for strong sell. The mean price target for the equity is at $124.50 while the highest price target suggested by the brokerage firms is $142.00 and low price target is $81.00. The mean price target is calculated keeping in view the consensus of 20 analysts.

    The mean revenue estimate for the ongoing quarter ending Sep 16 is $17.71B by 17 analysts. The average forecast of sales for the year ending Dec 16 is $72.08B by 19 financial experts.

    Earnings Summary

    In Johnson & Johnson (NYSE:JNJ) latest quarter ended on 30 Jun 2016, company revealed earnings of $1.74 a share. The reported earnings topped the analyst’s consensus by $0.06 with the surprise factor around 3.60%. In the matter of earnings surprises, it can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time.

    Analyst’s Report Preview: Church & Dwight Co. Inc. (NYSE:CHD)

    Church & Dwight Co. Inc. (NYSE:CHD) shares currently have a mean rating of 2.80 while 3 analysts have recommended the shares as ‘BUY’, 2 commented as ‘OUTPERFORM’ and 10 commented as ‘HOLD’. The rating score is on a scale of 1-5 where 1 stands for strong buy and 5 stands for sell. The mean price target for the company’s stock is $50.67 while the highest price target suggested by the analysts is $59.00 and low price target is $42.00. The mean price target is calculated keeping in view the consensus of 15 brokerage firms.

    Church & Dwight Co. Inc. (NYSE:CHD) has a mean revenue estimate for the ongoing quarter ending Sep 16 of $884.53M, according to 14 analysts. The average forecast of sales for the year ending Dec 16 is $3.51B by 19 analysts.

    Church & Dwight Co. Inc. (NYSE:CHD) went up 0.75% during trading on 10/17/2016, closing at $48.28. The stock had a trading capacity of 1.76M shares. The firm has a SMA 50 (Simple Moving Average) of $47.96 and a SMA 200-(Simple Moving Average) of $48.62. This appreciation has taken its current market value to12.40B and a price-to-earnings ratio to 28.14. Shares registered one year high at $53.49 and the one year low of $38.00.

    Earnings Overview For Church & Dwight Co. Inc.

    Company latest quarter ended on 30 Jun 2016. There were earnings of $0.43 per share. The reported earnings topped the analyst’s consensus by $0.03 with the surprise factor of 7.50%

    Return to headline | Return to top

56. Investment Research Analysts Opinion: Johnson & Johnson (NYSE:JNJ), Mylan N.V. (NASDAQ:MYL)

    Oct 18, 2016 | The Wellesley News

    By Rodolfo Page

    At the most recent close, Johnson & Johnson (NYSE:JNJ) tinted gains of +0.79% (+0.93 points) to US$118.49. The volume of 6.94 Million shares climbed up over an trading activity of 6.06 Million shares. EPS ratio determined by looking at last 12 month figures is 5.37. Over the same time span, the stock marked US$126.07 as its best level and the lowest price reached was US$94.28. The corporation has a market cap of US$326.1 Billion.

    Johnson & Johnson (NYSE:JNJ)’s earnings per share has been growing at a 2.8 percent rate over the past 5 year when average revenue increase was noted as 2.6 percent. The return on equity ratio or ROE stands at 20.9 percent while most common profitability ratio return on investment (ROI) was 14.7 percent. The company’s institutional ownership is monitored at 67 percent. The company’s net profit margin has achieved the current level of 21.2 percent and possesses 69.6 percent gross margin.

    FT reports, The 19 analysts offering 12 month price targets for Johnson & Johnson have a median target of 130.00, with a high estimate of 142.00 and a low estimate of 105.00. The median estimate represents a 10.58% increase from the last price of 117.56.

    Daily Analyst Recommendations

    A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 9 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 12 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

    Mylan N.V. (NASDAQ:MYL) is worth US$20.23 Billion and has recently fallen -0.14% to US$36.44. The latest exchange of 6.71 Million shares is below its average trading activity of 6.73 Million shares. The day began at US$36.69 but the price moved to US$36.09 at one point during the trading and finally capitulating to a session high of US$36.8. The stock tapped a 52-week high of US$55.51 while the mean 12-month price target for the shares is US$53.83.

    Currently, the stock carries a price to earnings ratio of 23.17, a price to book ratio of 1.78, and a price to sales ratio of 2.04. For the past 5 years, the company’s revenue has grown 11.6%, while the company’s earnings per share has grown 20.2%. With an institutional ownership near 64.7%, it carries an earnings per share ratio of 1.57.

    According to Financial Times, The 18 analysts offering 12 month price targets for Mylan NV have a median target of 53.50, with a high estimate of 66.00 and a low estimate of 43.00. The median estimate represents a 46.62% increase from the last price of 36.49.

    Inside Look At Analysts Reviews

    Latest analyst recommendations could offer little help to investors. The stock is a Buy among 12 brokerage firms polled by Factset Research. At present, 7 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.

    Return to headline | Return to top

Television Coverage

57. Squawk Box

    Oct 18, 2016 | CNBC

     http://app.criticalmention.com/app/#clip/view/24580931?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

     (03:37)

    Return to headline | Return to top

58. Bloomberg Daybreak

    Oct 18, 2016 | BLOOM-TV

     http://app.criticalmention.com/app/#clip/view/24581068?token=1f262742-0cd0-43e0-a677-9b779fc19bdb

    (06:02)

    Return to headline | Return to top

59. Squawk Box

    Oct 18, 2016 | CNBC

      http://app.criticalmention.com/app/#clip/view/24580788?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

    (00:23) 

    Return to headline | Return to top

60. Bloomberg Surveillance

    Oct 18, 2016 | BLOOM-TV

     http://app.criticalmention.com/app/#clip/view/24580802?token=1f262742-0cd0-43e0-a677-9b779fc19bdb 
    

    (00:22)

    Return to headline | Return to top

61. Bloomberg Surveillance

    Oct 18, 2016 | BLOOM-TV

     http://app.criticalmention.com/app/#clip/view/24580809?token=1f262742-0cd0-43e0-a677-9b779fc19bdb 
    

    (00:39)

     

    Return to headline | Return to top

62. Bloomberg Daybreak: Americas

    Oct 18, 2016 | BLOOM-TV

    http://app.criticalmention.com/app/#clip/view/24581302?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

    (00:28)

    Return to headline | Return to top

63. Squawk Box

    Oct 18, 2016 | CNBC

     http://app.criticalmention.com/app/#clip/view/24581329?token=1f262742-0cd0-43e0-a677-9b779fc19bdb

    (00:44) 

    Return to headline | Return to top

64. Bloomberg Daybreak: Americas

    Oct 18, 2016 | BLOOM-TV

     http://app.criticalmention.com/app/#clip/view/24582540?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

    (00:23) 

    Return to headline | Return to top

65. Bloomberg Radio Clip

    Oct 18, 2016 | Bloomberg

    By Bloomberg Markets (Radio)

     http://app.criticalmention.com/app/#clip/view/24584556?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

     (04:31)

    Return to headline | Return to top

66. Bloomberg Markets: European Close

    Oct 18, 2016 | BLOOM-TV

    View clip here: http://app.criticalmention.com/app/#clip/view/24583876?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

    (00:20)

    Return to headline | Return to top

67. Power Lunch

    Oct 18, 2016 | CNBC

    View clip here: http://app.criticalmention.com/app/#clip/view/24584682?token=74ea5693-5128-42c8-bc42-3b28fe421fd3

    (00:13)

    Return to headline | Return to top

68. After the Bell Clip

    Oct 19, 2016 | Fox Business News

    http://app.criticalmention.com/app/#clip/view/24586945?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e

    (00:22)

    Return to headline | Return to top

69. Fast Money

    Oct 19, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24593847?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e

    (01:19)

    Return to headline | Return to top

70. Nightly Business Report

    | FX

    http://app.criticalmention.com/app/#clip/view/24594057?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e

    (01:00)

    Return to headline | Return to top

71. Global Business

    Oct 19, 2016 | CCTV

    http://app.criticalmention.com/app/#clip/view/24594142?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e

    (00:15)

    Return to headline | Return to top

72. Squawk on the Street

    Oct 19, 2016 | CNBC

    http://app.criticalmention.com/app/#clip/view/24594183?token=bb9a9146-7e41-4c4e-83f5-2e0064a57b3e

    (00:16)

    Return to headline | Return to top